Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Colorectal Neoplasms

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 501 articles:
HTML format



Single Articles


    July 2021
  1. WANG D, O'Rourke D, Sanchez-Garcia JF, Cai T, et al
    Development of a liquid biopsy based purely quantitative digital droplet PCR assay for detection of MLH1 promoter methylation in colorectal cancer patients.
    BMC Cancer. 2021;21:797.
    PubMed     Abstract available


  2. FU Y, Chen X, Song Y, Huang X, et al
    The platelet to lymphocyte ratio is a potential inflammatory marker predicting the effects of adjuvant chemotherapy in patients with stage II colorectal cancer.
    BMC Cancer. 2021;21:792.
    PubMed     Abstract available


  3. FU D, Ren Y, Wang C, Yu L, et al
    LINC01287 facilitates proliferation, migration, invasion and EMT of colon cancer cells via miR-4500/MAP3K13 pathway.
    BMC Cancer. 2021;21:782.
    PubMed     Abstract available


  4. WANG S, Pang L, Liu Z, Meng X, et al
    SERPINE1 associated with remodeling of the tumor microenvironment in colon cancer progression: a novel therapeutic target.
    BMC Cancer. 2021;21:767.
    PubMed     Abstract available


  5. SHANG W, Yan C, Liu R, Chen L, et al
    Clinical significance of FBXW7 tumor suppressor gene mutations and expression in human colorectal cancer: a systemic review and meta-analysis.
    BMC Cancer. 2021;21:770.
    PubMed     Abstract available


  6. LAMBERT P, Pitz M, Singh H, Decker K, et al
    Evaluation of algorithms using administrative health and structured electronic medical record data to determine breast and colorectal cancer recurrence in a Canadian province : Using algorithms to determine breast and colorectal cancer recurrence.
    BMC Cancer. 2021;21:763.
    PubMed     Abstract available


    June 2021
  7. NILSSEN Y, Eriksen MT, Guren MG, Moller B, et al
    Factors associated with emergency-onset diagnosis, time to treatment and type of treatment in colorectal cancer patients in Norway.
    BMC Cancer. 2021;21:757.
    PubMed     Abstract available


  8. XU H, Lan Q, Huang Y, Zhang Y, et al
    The mechanisms of colorectal cancer cell mesenchymal-epithelial transition induced by hepatocyte exosome-derived miR-203a-3p.
    BMC Cancer. 2021;21:718.
    PubMed     Abstract available


  9. LEE G, Jeong S, Choi S, Kim KH, et al
    Associations between alcohol consumption and cardiovascular disease among long-term survivors of colorectal cancer: a population-based, retrospective cohort study.
    BMC Cancer. 2021;21:710.
    PubMed     Abstract available


  10. NIEMELAINEN S, Huhtala H, Ehrlich A, Kossi J, et al
    Surgical and functional outcomes and survival following Colon Cancer surgery in the aged: a study protocol for a prospective, observational multicentre study.
    BMC Cancer. 2021;21:698.
    PubMed     Abstract available


  11. NAKAJIMA H, Kotani D, Bando H, Kato T, et al
    REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.
    BMC Cancer. 2021;21:674.
    PubMed     Abstract available


    May 2021
  12. HAMMAD A, Zheng ZH, Namani A, Elshaer M, et al
    Transcriptome analysis of potential candidate genes and molecular pathways in colitis-associated colorectal cancer of Mkp-1-deficient mice.
    BMC Cancer. 2021;21:607.
    PubMed     Abstract available


  13. TIAN P, Zhu Y, Zhang C, Guo X, et al
    Retraction Note: Ras-ERK1/2 signaling contributes to the development of colorectal cancer via regulating H3K9ac.
    BMC Cancer. 2021;21:594.
    PubMed    


  14. SUSMI TF, Rahman A, Khan MMR, Yasmin F, et al
    Prognostic and clinicopathological insights of phosphodiesterase 9A gene as novel biomarker in human colorectal cancer.
    BMC Cancer. 2021;21:577.
    PubMed     Abstract available


  15. ADENIS A, Mazard T, Fraisse J, Chalbos P, et al
    FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.
    BMC Cancer. 2021;21:564.
    PubMed     Abstract available


  16. YANG S, Bian J, George TJ, Daily K, et al
    The association between cognitive impairment and breast and colorectal cancer screening utilization.
    BMC Cancer. 2021;21:539.
    PubMed     Abstract available


  17. ZOK J, Bienkowski M, Radecka B, Korniluk J, et al
    Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohort study.
    BMC Cancer. 2021;21:529.
    PubMed     Abstract available


  18. IKOMA T, Shimokawa M, Kotaka M, Matsumoto T, et al
    Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
    BMC Cancer. 2021;21:518.
    PubMed     Abstract available


    April 2021
  19. LEE SHF, Abdul Rahman H, Abidin N, Ong SK, et al
    Survival of colorectal cancer patients in Brunei Darussalam: comparison between 2002-09 and 2010-17.
    BMC Cancer. 2021;21:477.
    PubMed     Abstract available


  20. ORTEGA-MORAN JF, Azpeitia A, Sanchez-Peralta LF, Bote-Curiel L, et al
    Medical needs related to the endoscopic technology and colonoscopy for colorectal cancer diagnosis.
    BMC Cancer. 2021;21:467.
    PubMed     Abstract available


  21. ENGBERSEN MP, Rijsemus CJV, Nederend J, Aalbers AGJ, et al
    Dedicated MRI staging versus surgical staging of peritoneal metastases in colorectal cancer patients considered for CRS-HIPEC; the DISCO randomized multicenter trial.
    BMC Cancer. 2021;21:464.
    PubMed     Abstract available


  22. DE CASTRO E GLORIA H, Jesuino Nogueira L, Bencke Grudzinski P, da Costa Ghignatti PV, et al
    Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells.
    BMC Cancer. 2021;21:448.
    PubMed     Abstract available


  23. FRENNERED A, Scherman J, Buchwald P, Johnsson A, et al
    Patterns of pathologic lymph nodes in anal cancer: a PET-CT-based analysis with implications for radiotherapy treatment volumes.
    BMC Cancer. 2021;21:447.
    PubMed     Abstract available


  24. PAKU M, Uemura M, Kitakaze M, Fujino S, et al
    Impact of the preoperative prognostic nutritional index as a predictor for postoperative complications after resection of locally recurrent rectal cancer.
    BMC Cancer. 2021;21:435.
    PubMed     Abstract available


  25. KIANI B, Hashemi Amin F, Bagheri N, Bergquist R, et al
    Association between heavy metals and colon cancer: an ecological study based on geographical information systems in North-Eastern Iran.
    BMC Cancer. 2021;21:414.
    PubMed     Abstract available


  26. SAKAI N, Furukawa K, Takayashiki T, Kuboki S, et al
    Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases.
    BMC Cancer. 2021;21:412.
    PubMed     Abstract available


  27. ZHUANG Y, Wang H, Jiang D, Li Y, et al
    Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
    BMC Cancer. 2021;21:380.
    PubMed     Abstract available


  28. VANIA L, Morris G, Ferreira E, Weiss SFT, et al
    Knock-down of LRP/LR influences signalling pathways in late-stage colorectal carcinoma cells.
    BMC Cancer. 2021;21:392.
    PubMed     Abstract available


  29. HUANG CC, Liu FR, Feng Q, Pan XY, et al
    Correction to: RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480.
    BMC Cancer. 2021;21:361.
    PubMed    


  30. RIBEIRINHO-SOARES S, Padua D, Amaral AL, Valentini E, et al
    Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
    BMC Cancer. 2021;21:359.
    PubMed     Abstract available


  31. LI S, Yan G, Yue M, Wang L, et al
    Extracellular vesicles-derived microRNA-222 promotes immune escape via interacting with ATF3 to regulate AKT1 transcription in colorectal cancer.
    BMC Cancer. 2021;21:349.
    PubMed     Abstract available


  32. MAHMOOD RD, Shaw D, Descamps T, Zhou C, et al
    Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study.
    BMC Cancer. 2021;21:354.
    PubMed     Abstract available


    March 2021
  33. HUANG CC, Liu FR, Feng Q, Pan XY, et al
    RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480.
    BMC Cancer. 2021;21:321.
    PubMed     Abstract available


  34. SHIRAISHI T, Ikeda K, Tsukada Y, Nishizawa Y, et al
    High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer.
    BMC Cancer. 2021;21:302.
    PubMed     Abstract available


  35. LV Z, Liang Y, Liu H, Mo D, et al
    Association of chemotherapy with survival in stage II colon cancer patients who received radical surgery: a retrospective cohort study.
    BMC Cancer. 2021;21:306.
    PubMed     Abstract available


  36. XIAO J, Li W, Huang Y, Huang M, et al
    A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    BMC Cancer. 2021;21:282.
    PubMed     Abstract available


  37. WEN C, Feng X, Yuan H, Gong Y, et al
    Circ_0003266 sponges miR-503-5p to suppress colorectal cancer progression via regulating PDCD4 expression.
    BMC Cancer. 2021;21:284.
    PubMed     Abstract available


  38. SATO A, Matsubayashi K, Morishima T, Nakata K, et al
    Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study.
    BMC Cancer. 2021;21:264.
    PubMed     Abstract available


  39. KIRITANI S, Yoshimura K, Arita J, Kokudo T, et al
    A new rapid diagnostic system with ambient mass spectrometry and machine learning for colorectal liver metastasis.
    BMC Cancer. 2021;21:262.
    PubMed     Abstract available


  40. CHEN J, Song Y, Li M, Zhang Y, et al
    Comprehensive analysis of ceRNA networks reveals prognostic lncRNAs related to immune infiltration in colorectal cancer.
    BMC Cancer. 2021;21:255.
    PubMed     Abstract available


  41. BESUTTI G, Damato A, Venturelli F, Bonelli C, et al
    Baseline liver steatosis has no impact on liver metastases and overall survival in rectal cancer patients.
    BMC Cancer. 2021;21:253.
    PubMed     Abstract available


  42. ZHANG M, Yang J, Jiang H, Jiang H, et al
    Correlation between glucose metabolism parameters derived from FDG and tumor TNM stages and metastasis-associated proteins in colorectal carcinoma patients.
    BMC Cancer. 2021;21:258.
    PubMed     Abstract available


  43. ALBUQUERQUE A, Godfrey MAL, Cappello C, Pesola F, et al
    Multizonal anogenital neoplasia in women: a cohort analysis.
    BMC Cancer. 2021;21:232.
    PubMed     Abstract available


  44. DROGE LH, Hennies S, Lorenzen S, Conradi LC, et al
    Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer.
    BMC Cancer. 2021;21:219.
    PubMed     Abstract available


  45. LIN PC, Yeh YM, Chan RH, Lin BW, et al
    Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy.
    BMC Cancer. 2021;21:217.
    PubMed     Abstract available


  46. WONG SK, Hamm J, Shokoohi A, McGahan CE, et al
    Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment.
    BMC Cancer. 2021;21:215.
    PubMed     Abstract available


  47. FONSECA AS, Ramao A, Burger MC, de Souza JES, et al
    ETV4 plays a role on the primary events during the adenoma-adenocarcinoma progression in colorectal cancer.
    BMC Cancer. 2021;21:207.
    PubMed     Abstract available


    February 2021
  48. ARAUJO LH, Souza BM, Leite LR, Parma SAF, et al
    Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    BMC Cancer. 2021;21:193.
    PubMed     Abstract available


  49. WANG H, Gu D, Yu M, Hu Y, et al
    Variation rs9929218 and risk of the colorectal Cancer and adenomas: A meta-analysis.
    BMC Cancer. 2021;21:190.
    PubMed     Abstract available


  50. TAMPAKIS A, Tampaki EC, Nonni A, Kostakis ID, et al
    Correction to: High fascin-1 expression in colorectal cancer identifies patients at high risk for early disease recurrence and associated mortality.
    BMC Cancer. 2021;21:191.
    PubMed    


  51. YAN L, Chen H, Tang L, Jiang P, et al
    Super-enhancer-associated long noncoding RNA AC005592.2 promotes tumor progression by regulating OLFM4 in colorectal cancer.
    BMC Cancer. 2021;21:187.
    PubMed     Abstract available


  52. YUAN Y, Xiao WW, Xie WH, Cai PQ, et al
    Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection.
    BMC Cancer. 2021;21:179.
    PubMed     Abstract available


  53. JIANG S, Li Q, Liu Y, Zhang H, et al
    Activation of WNT7b autocrine eases metastasis of colorectal cancer via epithelial to mesenchymal transition and predicts poor prognosis.
    BMC Cancer. 2021;21:180.
    PubMed     Abstract available


  54. ATHANASIOS T, Ekaterini-Christina T, Afrodite N, Ioannis KD, et al
    High fascin-1 expression in colorectal cancer identifies patients at high risk for early disease recurrence and associated mortality.
    BMC Cancer. 2021;21:153.
    PubMed     Abstract available


  55. MOTSUKU L, Chen WC, Muchengeti MM, Naidoo M, et al
    Colorectal cancer incidence and mortality trends by sex and population group in South Africa: 2002-2014.
    BMC Cancer. 2021;21:129.
    PubMed     Abstract available


  56. XI Y, Jing Z, Wei W, Chun Z, et al
    Inhibitory effect of sodium butyrate on colorectal cancer cells and construction of the related molecular network.
    BMC Cancer. 2021;21:127.
    PubMed     Abstract available


  57. KAWAI S, Takeshima N, Hayasaka Y, Notsu A, et al
    Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis.
    BMC Cancer. 2021;21:116.
    PubMed     Abstract available


  58. IWAYA M, Ota H, Nakajima T, Uehara T, et al
    Most colitis associated carcinomas lack expression of LGR5: a preliminary study with implications for unique pathways of carcinogenesis compared to sporadic colorectal carcinoma.
    BMC Cancer. 2021;21:119.
    PubMed     Abstract available


    January 2021
  59. EL ALAMI Y, Essangri H, Majbar MA, Boutayeb S, et al
    Psychometric validation of the Moroccan version of the EORTC QLQ-C30 in colorectal Cancer patients: cross-sectional study and systematic literature review.
    BMC Cancer. 2021;21:99.
    PubMed     Abstract available


  60. CAO Y, Deng S, Yan L, Gu J, et al
    A nomogram based on pretreatment levels of serum bilirubin and total bile acid levels predicts survival in colorectal cancer patients.
    BMC Cancer. 2021;21:85.
    PubMed     Abstract available


  61. MARTINEZ-LAGO N, Fernandez-Montes A, Covela M, Brozos EM, et al
    Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.
    BMC Cancer. 2021;21:64.
    PubMed     Abstract available


  62. XU Y, Li C, Zheng CZ, Zhang YQ, et al
    Comparison of long-term outcomes between Lynch sydrome and sporadic colorectal cancer: a propensity score matching analysis.
    BMC Cancer. 2021;21:45.
    PubMed     Abstract available


  63. ZHOU S, Feng Q, Zhang J, Zhou H, et al
    High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy.
    BMC Cancer. 2021;21:41.
    PubMed     Abstract available


  64. HUANG C, Gu X, Zeng X, Chen B, et al
    Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study.
    BMC Cancer. 2021;21:30.
    PubMed     Abstract available


  65. CHEN X, Wu H, Feng J, Li Y, et al
    Transcriptome profiling unveils GAP43 regulates ABC transporters and EIF2 signaling in colorectal cancer cells.
    BMC Cancer. 2021;21:24.
    PubMed     Abstract available


  66. MIWA K, Oki E, Enomoto M, Ihara K, et al
    Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
    BMC Cancer. 2021;21:23.
    PubMed     Abstract available


  67. CONG J, Gong J, Yang C, Xia Z, et al
    MiR-200c/FUT4 axis prevents the proliferation of colon cancer cells by downregulating the Wnt/beta-catenin pathway.
    BMC Cancer. 2021;21:2.
    PubMed     Abstract available


    December 2020
  68. MOON B, Yang SJ, Park SM, Lee SH, et al
    LAD1 expression is associated with the metastatic potential of colorectal cancer cells.
    BMC Cancer. 2020;20:1180.
    PubMed     Abstract available


    November 2020
  69. ARNOLD A, Tronser M, Sers C, Ahadova A, et al
    Correction to: The majority of beta-catenin mutations in colorectal cancer is homozygous.
    BMC Cancer. 2020;20:1151.
    PubMed     Abstract available


  70. RUMPOLD H, Niedersuss-Beke D, Heiler C, Falch D, et al
    Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis.
    BMC Cancer. 2020;20:1149.
    PubMed     Abstract available


  71. ZHANG Z, Zheng S, Lin Y, Sun J, et al
    Genomics and prognosis analysis of epithelial-mesenchymal transition in colorectal cancer patients.
    BMC Cancer. 2020;20:1135.
    PubMed     Abstract available


  72. SATAKE H, Ando K, Oki E, Shimokawa M, et al
    Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.
    BMC Cancer. 2020;20:1116.
    PubMed     Abstract available


  73. CAO Y, Gu J, Yan L, Deng S, et al
    The value of haematological parameters and serum tumour markers for predicting KRAS mutations in 784 Chinese colorectal cancer patients: a retrospective analysis.
    BMC Cancer. 2020;20:1099.
    PubMed     Abstract available


  74. TAKAMIZAWA Y, Shida D, Boku N, Nakamura Y, et al
    Nutritional and inflammatory measures predict survival of patients with stage IV colorectal cancer.
    BMC Cancer. 2020;20:1092.
    PubMed     Abstract available


  75. GRIGORE B, Lewis R, Peters J, Robinson S, et al
    Development, validation and effectiveness of diagnostic prediction tools for colorectal cancer in primary care: a systematic review.
    BMC Cancer. 2020;20:1084.
    PubMed     Abstract available


  76. BARBIROU M, Woldu HG, Sghaier I, Bedoui SA, et al
    Western influenced lifestyle and Kv2.1 association as predicted biomarkers for Tunisian colorectal cancer.
    BMC Cancer. 2020;20:1086.
    PubMed     Abstract available


  77. HOYDAHL O, Edna TH, Xanthoulis A, Lydersen S, et al
    Long-term trends in colorectal cancer: incidence, localization, and presentation.
    BMC Cancer. 2020;20:1077.
    PubMed     Abstract available


  78. ZENG C, Xiong D, Cheng F, Luo Q, et al
    Retrospective analysis of LNM risk factors and the effect of chemotherapy in early colorectal cancer: A Chinese multicenter study.
    BMC Cancer. 2020;20:1067.
    PubMed     Abstract available


    October 2020
  79. ARNOLD A, Tronser M, Sers C, Ahadova A, et al
    The majority of beta-catenin mutations in colorectal cancer is homozygous.
    BMC Cancer. 2020;20:1038.
    PubMed     Abstract available


  80. DAU H, Safari A, Saad El Din K, McTaggart-Cowan H, et al
    Assessing how health information needs of individuals with colorectal cancer are met across the care continuum: an international cross-sectional survey.
    BMC Cancer. 2020;20:1031.
    PubMed     Abstract available


  81. JIANG Y, Yan X, Liu K, Shi Y, et al
    Discovering the molecular differences between right- and left-sided colon cancer using machine learning methods.
    BMC Cancer. 2020;20:1012.
    PubMed     Abstract available


  82. XU X, Yu Y, Shen M, Liu M, et al
    Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    BMC Cancer. 2020;20:1006.
    PubMed     Abstract available


  83. PENG Q, Shen Y, Zhao P, Cai S, et al
    Biomarker exploration of microRNA-203 as a promising substrate for predicting poor survival outcome in colorectal cancer.
    BMC Cancer. 2020;20:1003.
    PubMed     Abstract available


  84. PENG Z, Hou X, Huang Y, Xie T, et al
    Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China.
    BMC Cancer. 2020;20:990.
    PubMed     Abstract available


  85. JIN LP, Liu T, Meng FQ, Tai JD, et al
    Prognosis prediction model based on competing endogenous RNAs for recurrence of colon adenocarcinoma.
    BMC Cancer. 2020;20:968.
    PubMed     Abstract available


  86. KENNEDY SA, Morrissey ME, Dunne MR, O'Connell F, et al
    Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors.
    BMC Cancer. 2020;20:952.
    PubMed     Abstract available


  87. KIM N, Yoon HI, Kim JS, Koom WS, et al
    Simple calculation using anatomical features on pre-treatment verification CT for bladder volume estimation during radiation therapy for rectal cancer.
    BMC Cancer. 2020;20:942.
    PubMed     Abstract available


    September 2020
  88. MAZAKI J, Katsumata K, Kasahara K, Tago T, et al
    Neutrophil-to-lymphocyte ratio is a prognostic factor for colon cancer: a propensity score analysis.
    BMC Cancer. 2020;20:922.
    PubMed     Abstract available


  89. CHEN H, Luo J, Guo J
    Identification of an alternative splicing signature as an independent factor in colon cancer.
    BMC Cancer. 2020;20:904.
    PubMed     Abstract available


  90. YOO E, Lee J, Lertpatipanpong P, Ryu J, et al
    Anti-proliferative activity of A. Oxyphylla and its bioactive constituent nootkatone in colorectal cancer cells.
    BMC Cancer. 2020;20:881.
    PubMed     Abstract available


  91. DAVIS JS, Kanikarla-Marie P, Gagea M, Yu PL, et al
    Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development.
    BMC Cancer. 2020;20:871.
    PubMed     Abstract available


  92. FENG X, Wei G, Wang W, Zhang Y, et al
    Nomogram for individually predicting overall survival in rectal neuroendocrine tumours.
    BMC Cancer. 2020;20:865.
    PubMed     Abstract available


  93. FENG Y, Peng C, Zhu Y, Liu L, et al
    Biplane transrectal ultrasonography plus ultrasonic elastosonography and contrast-enhanced ultrasonography in T staging of rectal cancer.
    BMC Cancer. 2020;20:862.
    PubMed     Abstract available


  94. ZHANG Y, Yan L, Wu Y, Xu M, et al
    Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer.
    BMC Cancer. 2020;20:854.
    PubMed     Abstract available


  95. COEBERGH VAN DEN BRAAK RRJ, Ten Hoorn S, Sieuwerts AM, Tuynman JB, et al
    Interconnectivity between molecular subtypes and tumor stage in colorectal cancer.
    BMC Cancer. 2020;20:850.
    PubMed     Abstract available


  96. OKUYAMA T, Sameshima S, Takeshita E, Mitsui T, et al
    Myxoid stroma is associated with postoperative relapse in patients with stage II colon cancer.
    BMC Cancer. 2020;20:842.
    PubMed     Abstract available


  97. AL-KHAYAL K, Vaali-Mohammed MA, Elwatidy M, Traiki TB, et al
    Correction to: A novel coordination complex of platinum (PT) induces cell death in colorectal cancer by altering redox balance and modulating MAPK pathway.
    BMC Cancer. 2020;20:834.
    PubMed     Abstract available


  98. SHAMSEDDINE A, Zeidan YH, Kreidieh M, Khalifeh I, et al
    Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
    BMC Cancer. 2020;20:831.
    PubMed     Abstract available


    August 2020
  99. DAMATO A, Iachetta F, Antonuzzo L, Nasti G, et al
    Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
    BMC Cancer. 2020;20:822.
    PubMed     Abstract available


  100. TABUNG FK, Noonan A, Lee DH, Song M, et al
    Post-diagnosis dietary insulinemic potential and survival outcomes among colorectal cancer patients.
    BMC Cancer. 2020;20:817.
    PubMed     Abstract available


  101. SCHRAA SJ, van Rooijen KL, van der Kruijssen DEW, Rubio Alarcon C, et al
    Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
    BMC Cancer. 2020;20:790.
    PubMed     Abstract available


  102. ARTUS A, Tabchouri N, Iskander O, Michot N, et al
    Long term outcome of anastomotic leakage in patients undergoing low anterior resection for rectal cancer.
    BMC Cancer. 2020;20:780.
    PubMed     Abstract available


  103. VAN DEN BERG I, van de Weerd S, Roodhart JML, Vink GR, et al
    Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study.
    BMC Cancer. 2020;20:776.
    PubMed     Abstract available


  104. WANG Q, Ye F, Ma P, Che Y, et al
    Quantified MRI and 25OH-VitD3 can be used as effective biomarkers for patients with neoadjuvant chemotherapy-induced liver injury in CRCLM?
    BMC Cancer. 2020;20:767.
    PubMed     Abstract available


  105. BAQAR AR, Wilkins S, Wang W, Oliva K, et al
    Log odds of positive lymph nodes is prognostically equivalent to lymph node ratio in non-metastatic colon cancer.
    BMC Cancer. 2020;20:762.
    PubMed     Abstract available


  106. SARASQUETA C, Zunzunegui MV, Enriquez Navascues JM, Querejeta A, et al
    Gender differences in stage at diagnosis and preoperative radiotherapy in patients with rectal cancer.
    BMC Cancer. 2020;20:759.
    PubMed     Abstract available


  107. YANG H, Yao Z, Cui M, Xing J, et al
    Influence of tumor location on short- and long-term outcomes after laparoscopic surgery for rectal cancer: a propensity score matched cohort study.
    BMC Cancer. 2020;20:761.
    PubMed     Abstract available


  108. SHADMANI FK, Farzadfar F, Yoosefi M, Mansori K, et al
    Premature mortality of gastrointestinal cancer in Iran: trends and projections 2001-2030.
    BMC Cancer. 2020;20:752.
    PubMed     Abstract available


  109. SCHOTTKER B, Kuznia S, Laetsch DC, Czock D, et al
    Protocol of the VICTORIA study: personalized vitamin D supplementation for reducing or preventing fatigue and enhancing quality of life of patients with colorectal tumor - randomized intervention trial.
    BMC Cancer. 2020;20:739.
    PubMed     Abstract available


    July 2020
  110. HECKL SM, Pellinghaus M, Behrens HM, Kruger S, et al
    Questioning the IGF1 receptor's assigned role in CRC - a case for rehabilitation?
    BMC Cancer. 2020;20:704.
    PubMed     Abstract available


  111. EL ASRI A, Zarrouq B, El Kinany K, Bouguenouch L, et al
    Associations between nutritional factors and KRAS mutations in colorectal cancer: a systematic review.
    BMC Cancer. 2020;20:696.
    PubMed     Abstract available


  112. ONWUKA JU, Li D, Liu Y, Huang H, et al
    A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility.
    BMC Cancer. 2020;20:692.
    PubMed     Abstract available


  113. MIYO M, Kato T, Yoshino T, Yamanaka T, et al
    Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.
    BMC Cancer. 2020;20:687.
    PubMed     Abstract available


  114. AL-KHAYAL K, Vaali-Mohammed MA, Elwatidy M, Bin Traiki T, et al
    A novel coordination complex of platinum (PT) induces cell death in colorectal cancer by altering redox balance and modulating MAPK pathway.
    BMC Cancer. 2020;20:685.
    PubMed     Abstract available


  115. ANTONIOTTI C, Borelli B, Rossini D, Pietrantonio F, et al
    AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
    BMC Cancer. 2020;20:683.
    PubMed     Abstract available


  116. LU Y, Wang X, Li P, Zhang T, et al
    Clinical characteristics and prognosis of anal squamous cell carcinoma: a retrospective audit of 144 patients from 11 cancer hospitals in southern China.
    BMC Cancer. 2020;20:679.
    PubMed     Abstract available


  117. DE LACY FB, Roodbeen SX, Rios J, van Laarhoven J, et al
    Three-year outcome after transanal versus laparoscopic total mesorectal excision in locally advanced rectal cancer: a multicenter comparative analysis.
    BMC Cancer. 2020;20:677.
    PubMed     Abstract available


  118. HU F, Wang Q, Yang Z, Zhang Z, et al
    Network-based identification of biomarkers for colon adenocarcinoma.
    BMC Cancer. 2020;20:668.
    PubMed     Abstract available


  119. YANG SY, Kim MJ, Kye BH, Han YD, et al
    Prospective study of oncologic outcomes after laparoscopic modified complete mesocolic excision for non-metastatic right colon cancer (PIONEER study): study protocol of a multicentre single-arm trial.
    BMC Cancer. 2020;20:657.
    PubMed     Abstract available


  120. LIN JL, Lin JX, Zheng CH, Li P, et al
    Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis.
    BMC Cancer. 2020;20:638.
    PubMed     Abstract available


  121. WRIGHT CM, Halkett G, Carey Smith R, Moorin R, et al
    Sarcoma epidemiology and cancer-related hospitalisation in Western Australia from 1982 to 2016: a descriptive study using linked administrative data.
    BMC Cancer. 2020;20:625.
    PubMed     Abstract available


  122. RUHNAU J, Parczyk J, Danker K, Eickholt B, et al
    Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism.
    BMC Cancer. 2020;20:617.
    PubMed     Abstract available


  123. GUTIERREZ-STAMPA MA, Aguilar V, Sarasqueta C, Cubiella J, et al
    Impact of the faecal immunochemical test on colorectal cancer survival.
    BMC Cancer. 2020;20:616.
    PubMed     Abstract available


    June 2020
  124. KUO IM, Lee JJ, Wang YS, Chiang HC, et al
    Potential enhancement of host immunity and anti-tumor efficacy of nanoscale curcumin and resveratrol in colorectal cancers by modulated electro- hyperthermia.
    BMC Cancer. 2020;20:603.
    PubMed     Abstract available


  125. MOSKOWITZ JE, Doran AG, Lei Z, Busi SB, et al
    Integration of genomics, metagenomics, and metabolomics to identify interplay between susceptibility alleles and microbiota in adenoma initiation.
    BMC Cancer. 2020;20:600.
    PubMed     Abstract available


  126. TANG CT, Zeng L, Yang J, Zeng C, et al
    Nomograms that predict the survival of patients with adenocarcinoma in villous adenoma of the colorectum: a SEER-based study.
    BMC Cancer. 2020;20:608.
    PubMed     Abstract available


  127. ALTUNEL E, Roghani RS, Chen KY, Kim SY, et al
    Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer.
    BMC Cancer. 2020;20:592.
    PubMed     Abstract available


  128. YANG X, Wu W, Pan Y, Zhou Q, et al
    Immune-related genes in tumor-specific CD4(+) and CD8(+) T cells in colon cancer.
    BMC Cancer. 2020;20:585.
    PubMed     Abstract available


  129. YANG X, Zheng E, Ye L, Gu C, et al
    The effect of pericolic lymph nodes metastasis beyond 10 cm proximal to the tumor on patients with rectal cancer.
    BMC Cancer. 2020;20:573.
    PubMed     Abstract available


  130. DESHAYES E, Piron L, Bouvier A, Lapuyade B, et al
    Study protocol of the HYPER-LIV01 trial: a multicenter phase II, prospective and randomized study comparing simultaneous portal and hepatic vein embolization to portal vein embolization for hypertrophy of the future liver remnant before major hepatect
    BMC Cancer. 2020;20:574.
    PubMed     Abstract available


  131. PARAKRAMA R, Fogel E, Chandy C, Augustine T, et al
    Immune characterization of metastatic colorectal cancer patients post reovirus administration.
    BMC Cancer. 2020;20:569.
    PubMed     Abstract available


  132. MORRISSEY ME, Byrne R, Nulty C, McCabe NH, et al
    The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation.
    BMC Cancer. 2020;20:566.
    PubMed     Abstract available


  133. NEGARANDEH R, Salehifar E, Saghafi F, Jalali H, et al
    Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients.
    BMC Cancer. 2020;20:560.
    PubMed     Abstract available


  134. ITO M, Kodaira T, Koide Y, Okuda T, et al
    Role of high-dose salvage radiotherapy for oligometastases of the localised abdominal/pelvic lymph nodes: a retrospective study.
    BMC Cancer. 2020;20:540.
    PubMed     Abstract available


  135. MEHLIS K, Witte J, Surmann B, Kudlich M, et al
    The patient-level effect of the cost of Cancer care - financial burden in German Cancer patients.
    BMC Cancer. 2020;20:529.
    PubMed     Abstract available


  136. PENG Q, Shen Y, Zhao P, Cheng M, et al
    Biomarker roles identification of miR-106 family for predicting the risk and poor survival of colorectal cancer.
    BMC Cancer. 2020;20:506.
    PubMed     Abstract available


  137. CHANG H, Tao YL, Jiang W, Chen C, et al
    Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.
    BMC Cancer. 2020;20:498.
    PubMed     Abstract available


    May 2020
  138. NILSSEN Y, Brustugun OT, Eriksen MT, Haug ES, et al
    Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.
    BMC Cancer. 2020;20:488.
    PubMed     Abstract available


  139. BROUQUET A, Bachet JB, Huguet F, Karoui M, et al
    NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
    BMC Cancer. 2020;20:485.
    PubMed     Abstract available


  140. ZHU XD, Wang J, You QH, Jiang TA, et al
    An isolated vaginal metastasis from intestinal signet ring cell carcinoma: a case report and literature review.
    BMC Cancer. 2020;20:478.
    PubMed     Abstract available


  141. MAHAR AL, Kurdyak P, Hanna TP, Coburn NG, et al
    Cancer staging in individuals with a severe psychiatric illness: a cross-sectional study using population-based cancer registry data.
    BMC Cancer. 2020;20:476.
    PubMed     Abstract available


  142. BUCKSCH K, Zachariae S, Aretz S, Buttner R, et al
    Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study.
    BMC Cancer. 2020;20:460.
    PubMed     Abstract available


  143. YUAN J, Guo D, Li X, Chen J, et al
    Prognostic and diagnostic value of circRNA expression in colorectal carcinoma: a meta-analysis.
    BMC Cancer. 2020;20:448.
    PubMed     Abstract available


  144. SUN Y, Cao B, Zhou J
    Roles of DANCR/microRNA-518a-3p/MDMA ceRNA network in the growth and malignant behaviors of colon cancer cells.
    BMC Cancer. 2020;20:434.
    PubMed     Abstract available


  145. EYL RE, Thong MSY, Carr PR, Jansen L, et al
    Physical activity and long-term fatigue among colorectal cancer survivors - a population-based prospective study.
    BMC Cancer. 2020;20:438.
    PubMed     Abstract available


  146. DAVIDSEN J, Jessen SB, Watt SK, Larsen S, et al
    CDX2 expression and perioperative patient serum affects the adhesion properties of cultured colon cancer cells.
    BMC Cancer. 2020;20:426.
    PubMed     Abstract available


  147. ZHANG H, Yuan L, Liu L, Yan C, et al
    Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
    BMC Cancer. 2020;20:416.
    PubMed     Abstract available


  148. SALIMZADEH H, Lindskog EB, Gustavsson B, Wettergren Y, et al
    Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
    BMC Cancer. 2020;20:409.
    PubMed     Abstract available


  149. TSUKUI H, Horie H, Koinuma K, Ohzawa H, et al
    CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model.
    BMC Cancer. 2020;20:411.
    PubMed     Abstract available


  150. LI X, Sun K, Liao X, Gao H, et al
    Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component.
    BMC Cancer. 2020;20:400.
    PubMed     Abstract available


  151. CHEN H, Luo J, Guo J
    Development and validation of a five-immune gene prognostic risk model in colon cancer.
    BMC Cancer. 2020;20:395.
    PubMed     Abstract available


  152. CALCATERRA SL, Burnett-Hartman AN, Powers JD, Corley DA, et al
    A population-based survey to assess the association between cannabis and quality of life among colorectal cancer survivors.
    BMC Cancer. 2020;20:373.
    PubMed     Abstract available


  153. PARK JH, Lee DH, Kim SI, Kim NK, et al
    Moderate to vigorous physical activity participation associated with better quality of life among breast and colorectal cancer survivors in Korea.
    BMC Cancer. 2020;20:365.
    PubMed     Abstract available


    April 2020
  154. WU P, Zhou Q, Zhu H, Zhuang Y, et al
    Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon.
    BMC Cancer. 2020;20:354.
    PubMed     Abstract available


  155. KITAGAWA Y, Osumi H, Shinozaki E, Ota Y, et al
    Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective stud
    BMC Cancer. 2020;20:358.
    PubMed     Abstract available


  156. ERFANI M, Hosseini SV, Mokhtari M, Zamani M, et al
    Altered ARID1A expression in colorectal cancer.
    BMC Cancer. 2020;20:350.
    PubMed     Abstract available


  157. KIM S, Buecher B, Andre T, Jary M, et al
    Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
    BMC Cancer. 2020;20:352.
    PubMed     Abstract available


  158. THERKILDSEN C, Rasmussen M, Smith-Hansen L, Kallemose T, et al
    Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort.
    BMC Cancer. 2020;20:345.
    PubMed     Abstract available


  159. NAKAJIMA T, Uehara T, Iwaya M, Kobayashi Y, et al
    Characterization of LGR5 expression in poorly differentiated colorectal carcinoma with mismatch repair protein deficiency.
    BMC Cancer. 2020;20:319.
    PubMed     Abstract available


  160. LI X, Yu W, Liang C, Xu Y, et al
    INHBA is a prognostic predictor for patients with colon adenocarcinoma.
    BMC Cancer. 2020;20:305.
    PubMed     Abstract available


  161. MUKUND K, Syulyukina N, Ramamoorthy S, Subramaniam S, et al
    Right and left-sided colon cancers - specificity of molecular mechanisms in tumorigenesis and progression.
    BMC Cancer. 2020;20:317.
    PubMed     Abstract available


  162. STEEGHS EMP, Kroeze LI, Tops BBJ, van Kempen LC, et al
    Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
    BMC Cancer. 2020;20:291.
    PubMed     Abstract available


  163. EL DIN KS, Loree JM, Sayre EC, Gill S, et al
    Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review.
    BMC Cancer. 2020;20:288.
    PubMed     Abstract available


  164. ORJUELA S, Menigatti M, Schraml P, Kambakamba P, et al
    The DNA hypermethylation phenotype of colorectal cancer liver metastases resembles that of the primary colorectal cancers.
    BMC Cancer. 2020;20:290.
    PubMed     Abstract available


    March 2020
  165. KOSARI F, Taheri M, Moradi A, Hakimi Alni R, et al
    Evaluation of cinnamon extract effects on clbB gene expression and biofilm formation in Escherichia coli strains isolated from colon cancer patients.
    BMC Cancer. 2020;20:267.
    PubMed     Abstract available


  166. WATANABE K, Katayama K, Yoshioka T, Narimatsu H, et al
    Impact of individual background on the unmet needs of cancer survivors and caregivers - a mixed-methods analysis.
    BMC Cancer. 2020;20:263.
    PubMed     Abstract available


  167. CAI Z, Xie X, Chen Y, Chen Z, et al
    Risk factor analysis for inaccurate pre-operative MRI staging in rectal cancer.
    BMC Cancer. 2020;20:253.
    PubMed     Abstract available


  168. SCHLIEMANN D, Paramasivam D, Dahlui M, Cardwell CR, et al
    Change in public awareness of colorectal cancer symptoms following the Be Cancer Alert Campaign in the multi-ethnic population of Malaysia.
    BMC Cancer. 2020;20:252.
    PubMed     Abstract available


  169. SIEBENHUNER AR, Guller U, Warschkow R
    Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases.
    BMC Cancer. 2020;20:246.
    PubMed     Abstract available


  170. ZHOU F, Tang D, Xu Y, He H, et al
    Identification of microRNAs and their Endonucleolytic Cleavaged target mRNAs in colorectal cancer.
    BMC Cancer. 2020;20:242.
    PubMed     Abstract available


  171. JIN XH, Lu S, Wang AF
    Expression and clinical significance of miR-4516 and miR-21-5p in serum of patients with colorectal cancer.
    BMC Cancer. 2020;20:241.
    PubMed     Abstract available


  172. LYHNE JD, Smith A'B, Frostholm L, Fink P, et al
    Study protocol: a randomized controlled trial comparing the efficacy of therapist guided internet-delivered cognitive therapy (TG-iConquerFear) with augmented treatment as usual in reducing fear of cancer recurrence in Danish colorectal cancer survivo
    BMC Cancer. 2020;20:223.
    PubMed     Abstract available


  173. LI J, Xu X, Jiang Y, Hansbro NG, et al
    Elastin is a key factor of tumor development in colorectal cancer.
    BMC Cancer. 2020;20:217.
    PubMed     Abstract available


  174. XIA LJ, Li W, Zhai JC, Yan CW, et al
    Significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio and prognostic nutritional index for predicting clinical outcomes in T1-2 rectal cancer.
    BMC Cancer. 2020;20:208.
    PubMed     Abstract available


  175. PAOLISSO P, Saturi G, Foa A, Saponara M, et al
    Primary malignant pericardial tumour in Lynch syndrome.
    BMC Cancer. 2020;20:191.
    PubMed     Abstract available


    February 2020
  176. KOWALCZYK M, Orlowski M, Klepacki L, Zinkiewicz K, et al
    Rectal aberrant crypt foci (ACF) as a predictor of benign and malignant neoplastic lesions in the large intestine.
    BMC Cancer. 2020;20:133.
    PubMed     Abstract available


  177. XU R, Wang W, Zhu B, Lin X, et al
    Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China.
    BMC Cancer. 2020;20:131.
    PubMed     Abstract available


  178. MIELE E, Abballe L, Spinelli GP, Besharat ZM, et al
    BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.
    BMC Cancer. 2020;20:129.
    PubMed     Abstract available


  179. SHEN Y, Guan Y, Hummel JJ, Shyu CR, et al
    Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer.
    BMC Cancer. 2020;20:124.
    PubMed     Abstract available


  180. PRESTON JL, Stiffler N
    Epigenetic loss of heterozygosity of Apc and an inflammation-associated mutational signature detected in Lrig1(+/-)-driven murine colonic adenomas.
    BMC Cancer. 2020;20:126.
    PubMed     Abstract available


  181. PERROTT S, Laurie K, Laws K, Johnes A, et al
    Young-onset colorectal cancer in the North East of Scotland: survival, clinico-pathological features and genetics.
    BMC Cancer. 2020;20:108.
    PubMed     Abstract available


  182. NOWAK RG, Nnaji CH, Dauda W, Mitchell A, et al
    Satisfaction with high-resolution anoscopy for anal cancer screening among men who have sex with men: a cross-sectional survey in Abuja, Nigeria.
    BMC Cancer. 2020;20:98.
    PubMed     Abstract available


  183. CHEN F, Qu M, Zhang F, Tan Z, et al
    IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?
    BMC Cancer. 2020;20:92.
    PubMed     Abstract available


  184. IVESON T, Carter AM, Shiu KK, Spooner C, et al
    Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
    BMC Cancer. 2020;20:91.
    PubMed     Abstract available


    January 2020
  185. MANOHARAN V, Karunanayake EH, Tennekoon KH, De Silva S, et al
    Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
    BMC Cancer. 2020;20:72.
    PubMed     Abstract available


  186. BOILEVE A, Maillard A, Wagner M, Dromain C, et al
    Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)-
    BMC Cancer. 2020;20:74.
    PubMed     Abstract available


  187. HAN JG, Wang ZJ, Zeng WG, Wang YB, et al
    Efficacy and safety of self-expanding metallic stent placement followed by neoadjuvant chemotherapy and scheduled surgery for treatment of obstructing left-sided colonic cancer.
    BMC Cancer. 2020;20:57.
    PubMed     Abstract available


  188. NOH BJ, Kwak JY, Eom DW
    Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    BMC Cancer. 2020;20:58.
    PubMed     Abstract available


  189. FOWLER H, Belot A, Ellis L, Maringe C, et al
    Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers.
    BMC Cancer. 2020;20:2.
    PubMed     Abstract available


  190. ARIANS N, Hafner M, Krisam J, Lang K, et al
    Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) - a prospective, randomized, 2-armed phase-II-trial.
    BMC Cancer. 2020;20:52.
    PubMed     Abstract available


  191. SIGNAL V, Jackson C, Signal L, Hardie C, et al
    Improving management of comorbidity in patients with colorectal cancer using comprehensive medical assessment: a pilot study.
    BMC Cancer. 2020;20:50.
    PubMed     Abstract available


  192. LICHTHARDT S, Wagner J, Lob S, Matthes N, et al
    Pathological complete response due to a prolonged time interval between preoperative chemoradiation and surgery in locally advanced rectal cancer: analysis from the German StuDoQ|Rectalcarcinoma registry.
    BMC Cancer. 2020;20:49.
    PubMed     Abstract available


  193. KOHOUTOVA D, Forstlova M, Moravkova P, Cyrany J, et al
    Bacteriocin production by mucosal bacteria in current and previous colorectal neoplasia.
    BMC Cancer. 2020;20:39.
    PubMed     Abstract available


  194. WANG Q, Wang Z, Wu Y, Klinke DJ 2nd, et al
    An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer.
    BMC Cancer. 2020;20:26.
    PubMed     Abstract available


  195. KAWAMURA H, Morishima T, Sato A, Honda M, et al
    Effect of adjuvant chemotherapy on survival benefit in stage III colon cancer patients stratified by age: a Japanese real-world cohort study.
    BMC Cancer. 2020;20:19.
    PubMed     Abstract available


  196. QADERI SM, Wijffels NAT, Bremers AJA, de Wilt JHW, et al
    Major differences in follow-up practice of patients with colorectal cancer; results of a national survey in the Netherlands.
    BMC Cancer. 2020;20:22.
    PubMed     Abstract available


    December 2019
  197. WANG X, Yu Q, Ghareeb WM, Zhang Y, et al
    Downregulated SPINK4 is associated with poor survival in colorectal cancer.
    BMC Cancer. 2019;19:1258.
    PubMed     Abstract available


  198. ZHANG X, Sun H, Chen W, He X, et al
    Elevated expression of AGGF1 predicts poor prognosis and promotes the metastasis of colorectal cancer.
    BMC Cancer. 2019;19:1252.
    PubMed     Abstract available


  199. KOTANI D, Kuboki Y, Horasawa S, Kaneko A, et al
    Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    BMC Cancer. 2019;19:1253.
    PubMed     Abstract available


  200. SASTRE D, Baiochi J, de Souza Lima IM, Canto de Souza F, et al
    Focused screening reveals functional effects of microRNAs differentially expressed in colorectal cancer.
    BMC Cancer. 2019;19:1239.
    PubMed     Abstract available


  201. SONG N, Lee J, Cho S, Kim J, et al
    Evaluation of gene-environment interactions for colorectal cancer susceptibility loci using case-only and case-control designs.
    BMC Cancer. 2019;19:1231.
    PubMed     Abstract available


  202. ZHANG X, Browman G, Siu W, Basen-Engquist KM, et al
    The BE GONE trial study protocol: a randomized crossover dietary intervention of dry beans targeting the gut microbiome of overweight and obese patients with a history of colorectal polyps or cancer.
    BMC Cancer. 2019;19:1233.
    PubMed     Abstract available


  203. LIU X, Fu J, Bi H, Ge A, et al
    DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients.
    BMC Cancer. 2019;19:1212.
    PubMed     Abstract available


  204. JANG YC, Huang HL, Leung CY
    Association of hormone replacement therapy with mortality in colorectal cancer survivor: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:1199.
    PubMed     Abstract available


  205. SHANG L, Fang Z, Liu J, Du F, et al
    Case report of ascending colon cancer and multiple jejunal GISTs in a patient with neurofibromatosis type 1 (NF1).
    BMC Cancer. 2019;19:1196.
    PubMed     Abstract available


  206. MANCEAU G, Brouquet A, Chaibi P, Passot G, et al
    Multicenter phase III randomized trial comparing laparoscopy and laparotomy for colon cancer surgery in patients older than 75 years: the CELL study, a Federation de Recherche en Chirurgie (FRENCH) trial.
    BMC Cancer. 2019;19:1185.
    PubMed     Abstract available


  207. WEBER S, Koschade SE, Hoffmann CM, Dubash TD, et al
    The notch target gene HEYL modulates metastasis forming capacity of colorectal cancer patient-derived spheroid cells in vivo.
    BMC Cancer. 2019;19:1181.
    PubMed     Abstract available


    November 2019
  208. PURCELL RV, Schmeier S, Lau YC, Pearson JF, et al
    Molecular subtyping improves prognostication of Stage 2 colorectal cancer.
    BMC Cancer. 2019;19:1155.
    PubMed     Abstract available


  209. GARCIA-GARCIA T, Carmona-Bayonas A, Jimenez-Fonseca P, Jara C, et al
    Biopsychosocial and clinical characteristics in patients with resected breast and colon cancer at the beginning and end of adjuvant treatment.
    BMC Cancer. 2019;19:1143.
    PubMed     Abstract available


  210. WANG HE, Liao YC, Hu JM, Wu WC, et al
    Correlation between kidney transplantation and colorectal cancer in hemodialysis patients: A nationwide, retrospective, population-based cohort study.
    BMC Cancer. 2019;19:1120.
    PubMed     Abstract available


  211. CALAPRE L, Warburton L, Millward M, Gray ES, et al
    Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report.
    BMC Cancer. 2019;19:1109.
    PubMed     Abstract available


  212. XU Y, Xu Q, Ma Y, Duan J, et al
    Characterizing MRI features of rectal cancers with different KRAS status.
    BMC Cancer. 2019;19:1111.
    PubMed     Abstract available


  213. MUSSELWHITE LW, Redding TS 4th, Sims KJ, O'Leary MC, et al
    Advanced neoplasia in Veterans at screening colonoscopy using the National Cancer Institute Risk Assessment Tool.
    BMC Cancer. 2019;19:1097.
    PubMed     Abstract available


  214. LI JB, Luo S, Wong MCS, Li C, et al
    Longitudinal associations between BMI change and the risks of colorectal cancer incidence, cancer-relate and all-cause mortality among 81,388 older adults : BMI change and the risks of colorectal cancer incidence and mortality.
    BMC Cancer. 2019;19:1082.
    PubMed     Abstract available


  215. SHENG H, Wei X, Mao M, He J, et al
    Adenocarcinoma with mixed subtypes is a rare but aggressive histologic subtype in colorectal cancer.
    BMC Cancer. 2019;19:1071.
    PubMed     Abstract available


  216. KALMAR A, Nagy ZB, Galamb O, Csabai I, et al
    Genome-wide expression profiling in colorectal cancer focusing on lncRNAs in the adenoma-carcinoma transition.
    BMC Cancer. 2019;19:1059.
    PubMed     Abstract available


  217. AHIKO Y, Shida D, Horie T, Tanabe T, et al
    Controlling nutritional status (CONUT) score as a preoperative risk assessment index for older patients with colorectal cancer.
    BMC Cancer. 2019;19:946.
    PubMed     Abstract available


  218. STRICKLER JH, Rushing CN, Niedzwiecki D, McLeod A, et al
    A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
    BMC Cancer. 2019;19:1032.
    PubMed     Abstract available


  219. MARTIN SZ, Wagner DC, Horner N, Horst D, et al
    Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer.
    BMC Cancer. 2019;19:1030.
    PubMed     Abstract available


  220. TROTSYUK I, Sparschuh H, Muller AJ, Neumann K, et al
    Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy.
    BMC Cancer. 2019;19:1033.
    PubMed     Abstract available


    October 2019
  221. LI J, Kong XX, Zhou JJ, Song YM, et al
    Fast-track multidisciplinary treatment versus conventional treatment for colorectal cancer: a multicenter, open-label randomized controlled study.
    BMC Cancer. 2019;19:988.
    PubMed     Abstract available


  222. JOHANSEN AFB, Kassentoft CG, Knudsen M, Laursen MB, et al
    Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients.
    BMC Cancer. 2019;19:971.
    PubMed     Abstract available


  223. ADVANI SM, Advani PS, Brown DW, DeSantis SM, et al
    Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer.
    BMC Cancer. 2019;19:964.
    PubMed     Abstract available


  224. LI C, He X, Zhang L, Li L, et al
    A pair-wise meta-analysis highlights circular RNAs as potential biomarkers for colorectal cancer.
    BMC Cancer. 2019;19:957.
    PubMed     Abstract available


  225. YE SB, Cheng YK, Zhang L, Wang XP, et al
    Prognostic value of estrogen receptor-alpha and progesterone receptor in curatively resected colorectal cancer: a retrospective analysis with independent validations.
    BMC Cancer. 2019;19:933.
    PubMed     Abstract available


    September 2019
  226. MIZUSHIMA T, Ikeda M, Kato T, Ikeda A, et al
    Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study.
    BMC Cancer. 2019;19:929.
    PubMed     Abstract available


  227. SAVOIE MB, Laffan A, Brickman C, Daniels B, et al
    A multi-disciplinary model of survivorship care following definitive chemoradiation for anal cancer.
    BMC Cancer. 2019;19:906.
    PubMed     Abstract available


  228. OTTAIANO A, Scala S, Normanno N, Napolitano M, et al
    Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.
    BMC Cancer. 2019;19:899.
    PubMed     Abstract available


  229. HAGHI F, Goli E, Mirzaei B, Zeighami H, et al
    The association between fecal enterotoxigenic B. fragilis with colorectal cancer.
    BMC Cancer. 2019;19:879.
    PubMed     Abstract available


  230. CONRADI LC, Spitzner M, Metzger AL, Kisly M, et al
    Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer.
    BMC Cancer. 2019;19:880.
    PubMed     Abstract available


    August 2019
  231. AL-HUSSEINI MJ, Saad AM, Mohamed HH, Alkhayat MA, et al
    Impact of prior malignancies on outcome of colorectal cancer; revisiting clinical trial eligibility criteria.
    BMC Cancer. 2019;19:863.
    PubMed     Abstract available


  232. LI M, Olver I, Keefe D, Holden C, et al
    Pre-diagnostic colonoscopies reduce cancer mortality - results from linked population-based data in South Australia.
    BMC Cancer. 2019;19:856.
    PubMed     Abstract available


  233. ANTOUN S, Bayar MA, Dyevre V, Lanoy E, et al
    No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer.
    BMC Cancer. 2019;19:847.
    PubMed     Abstract available


  234. LAWRANCE S, Bui C, Mahindra V, Arcorace M, et al
    Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.
    BMC Cancer. 2019;19:850.
    PubMed     Abstract available


  235. YOU Q, Fang Y, Li C, Tan Y, et al
    Multiple metastases of bones and sigmoid colon after mastectomy for ductal carcinoma in situ of the breast: a case report.
    BMC Cancer. 2019;19:844.
    PubMed     Abstract available


  236. WAN N, Weinberg D, Liu TY, Niehaus K, et al
    Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA.
    BMC Cancer. 2019;19:832.
    PubMed     Abstract available


  237. LI H, Jin X, Liu B, Zhang P, et al
    CircRNA CBL.11 suppresses cell proliferation by sponging miR-6778-5p in colorectal cancer.
    BMC Cancer. 2019;19:826.
    PubMed     Abstract available


  238. PERILLI L, Tessarollo S, Albertoni L, Curtarello M, et al
    Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer.
    BMC Cancer. 2019;19:821.
    PubMed     Abstract available


  239. XIE X, Yin J, Zhou Z, Dang C, et al
    Young age increases the risk for lymph node metastasis in patients with early Colon Cancer.
    BMC Cancer. 2019;19:803.
    PubMed     Abstract available


  240. TANAKA T, Sato T, Nishiofuku H, Masada T, et al
    Selective TACE with irinotecan-loaded 40 mum microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study.
    BMC Cancer. 2019;19:758.
    PubMed     Abstract available


    July 2019
  241. IMAIZUMI J, Shida D, Narita Y, Miyakita Y, et al
    Prognostic factors of brain metastases from colorectal cancer.
    BMC Cancer. 2019;19:755.
    PubMed     Abstract available


  242. DAPPER H, Schiller K, Munch S, Peeken JC, et al
    Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines.
    BMC Cancer. 2019;19:742.
    PubMed     Abstract available


  243. SARASQUETA C, Perales A, Escobar A, Bare M, et al
    Impact of age on the use of adjuvant treatments in patients undergoing surgery for colorectal cancer: patients with stage III colon or stage II/III rectal cancer.
    BMC Cancer. 2019;19:735.
    PubMed     Abstract available


  244. FERNANDEZ-BANARES F, Cleries R, Boadas J, Ribes J, et al
    Prediction of advanced colonic neoplasm in symptomatic patients: a scoring system to prioritize colonoscopy (COLONOFIT study).
    BMC Cancer. 2019;19:734.
    PubMed     Abstract available


  245. TANABE T, Shida D, Komukai S, Nakamura Y, et al
    Long-term outcomes after surgical dissection of inguinal lymph node metastasis from rectal or anal canal adenocarcinoma.
    BMC Cancer. 2019;19:733.
    PubMed     Abstract available


  246. CHAKROBORTY D, Emani MR, Klen R, Bockelman C, et al
    L1TD1 - a prognostic marker for colon cancer.
    BMC Cancer. 2019;19:727.
    PubMed     Abstract available


  247. GEMOLL T, Miroll E, Klein O, Lischka A, et al
    Spatial UBE2N protein expression indicates genomic instability in colorectal cancers.
    BMC Cancer. 2019;19:710.
    PubMed     Abstract available


  248. GUAN X, Ma CX, Quan JC, Li S, et al
    A clinical model to predict the risk of synchronous bone metastasis in newly diagnosed colorectal cancer: a population-based study.
    BMC Cancer. 2019;19:704.
    PubMed     Abstract available


  249. BENCSIKOVA B, Budinska E, Selingerova I, Pilatova K, et al
    Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.
    BMC Cancer. 2019;19:687.
    PubMed     Abstract available


  250. GAO Y, Nan X, Shi X, Mu X, et al
    SREBP1 promotes the invasion of colorectal cancer accompanied upregulation of MMP7 expression and NF-kappaB pathway activation.
    BMC Cancer. 2019;19:685.
    PubMed     Abstract available


  251. ALWERS E, Blaker H, Walter V, Jansen L, et al
    External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS.
    BMC Cancer. 2019;19:681.
    PubMed     Abstract available


  252. DUDANI S, Marginean H, Tang PA, Monzon JG, et al
    Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.
    BMC Cancer. 2019;19:664.
    PubMed     Abstract available


  253. ADLARD KN, Jenkins DG, Salisbury CE, Bolam KA, et al
    Peer support for the maintenance of physical activity and health in cancer survivors: the PEER trial - a study protocol of a randomised controlled trial.
    BMC Cancer. 2019;19:656.
    PubMed     Abstract available


  254. NG TH, Sham KWY, Xie CM, Ng SSM, et al
    Eukaryotic elongation factor-2 kinase expression is an independent prognostic factor in colorectal cancer.
    BMC Cancer. 2019;19:649.
    PubMed     Abstract available


    June 2019
  255. CAVAGNARI MAV, Silva TD, Pereira MAH, Sauer LJ, et al
    Impact of genetic mutations and nutritional status on the survival of patients with colorectal cancer.
    BMC Cancer. 2019;19:644.
    PubMed     Abstract available


  256. CHEN SH, Tsai HL, Jiang JK, Sung YC, et al
    Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol.
    BMC Cancer. 2019;19:640.
    PubMed     Abstract available


  257. PETERSEN CH, Mahmood B, Badsted C, Dahlby T, et al
    Possible predisposition for colorectal carcinogenesis due to altered gene expressions in normal appearing mucosa from patients with colorectal neoplasia.
    BMC Cancer. 2019;19:643.
    PubMed     Abstract available


  258. TERAZAWA T, Kato T, Goto M, Sakai D, et al
    First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602.
    BMC Cancer. 2019;19:623.
    PubMed     Abstract available


  259. SONG Z, Chen E, Qian J, Xu J, et al
    Serum chitinase activity prognosticates metastasis of colorectal cancer.
    BMC Cancer. 2019;19:629.
    PubMed     Abstract available


  260. JIANG Y, Sun Y, Hu J, Yu N, et al
    A germline mutation in Rab43 gene identified from a cancer family predisposes to a hereditary liver-colon cancer syndrome.
    BMC Cancer. 2019;19:613.
    PubMed     Abstract available


  261. WANG H, Wang X, Xu L, Zhang J, et al
    Analysis of the transcriptomic features of microsatellite instability subtype colon cancer.
    BMC Cancer. 2019;19:605.
    PubMed     Abstract available


  262. FENG Y, Qian W, Zhang Y, Peng W, et al
    CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT/CCND1 pathway in vitro and in vivo.
    BMC Cancer. 2019;19:576.
    PubMed     Abstract available


  263. CALLEBOUT E, Ribeiro SM, Laurent S, De Man M, et al
    Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
    BMC Cancer. 2019;19:567.
    PubMed     Abstract available


  264. LEKOANE KMB, Kuupiel D, Mashamba-Thompson TP, Ginindza TG, et al
    Evidence on the prevalence, incidence, mortality and trends of human papilloma virus-associated cancers in sub-Saharan Africa: systematic scoping review.
    BMC Cancer. 2019;19:563.
    PubMed     Abstract available


  265. VRINTEN C, Gallagher A, Waller J, Marlow LAV, et al
    Cancer stigma and cancer screening attendance: a population based survey in England.
    BMC Cancer. 2019;19:566.
    PubMed     Abstract available


  266. CARRATO A, Benavides M, Massuti B, Ferreiro-Monteagudo R, et al
    First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
    BMC Cancer. 2019;19:533.
    PubMed     Abstract available


  267. SAIJO S, Kuwano Y, Tange S, Rokutan K, et al
    A novel long non-coding RNA from the HOXA6-HOXA5 locus facilitates colon cancer cell growth.
    BMC Cancer. 2019;19:532.
    PubMed     Abstract available


  268. TSAOUSIS GN, Papadopoulou E, Apessos A, Agiannitopoulos K, et al
    Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
    BMC Cancer. 2019;19:535.
    PubMed     Abstract available


    May 2019
  269. ROQUETTE R, Painho M, Nunes B
    Geographical patterns of the incidence and mortality of colorectal cancer in mainland Portugal municipalities (2007-2011).
    BMC Cancer. 2019;19:512.
    PubMed     Abstract available


  270. CHEN Y, Yang X, Wen Z, Liu Y, et al
    Association between high-resolution MRI-detected extramural vascular invasion and tumour microcirculation estimated by dynamic contrast-enhanced MRI in rectal cancer: preliminary results.
    BMC Cancer. 2019;19:498.
    PubMed     Abstract available


  271. ABRAHAMSSON H, Porojnicu AC, Lindstrom JC, Dueland S, et al
    High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer.
    BMC Cancer. 2019;19:488.
    PubMed     Abstract available


  272. KIM EG, Kim JO, Park HS, Ryu CS, et al
    Genetic associations between the miRNA polymorphisms miR-130b (rs373001), miR-200b (rs7549819), and miR-495 (rs2281611) and colorectal cancer susceptibility.
    BMC Cancer. 2019;19:480.
    PubMed     Abstract available


  273. WANG F, He MM, Wang ZX, Li S, et al
    Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer.
    BMC Cancer. 2019;19:460.
    PubMed     Abstract available


  274. BURM R, Thewes B, Rodwell L, Kievit W, et al
    Long-term efficacy and cost-effectiveness of blended cognitive behavior therapy for high fear of recurrence in breast, prostate and colorectal Cancer survivors: follow-up of the SWORD randomized controlled trial.
    BMC Cancer. 2019;19:462.
    PubMed     Abstract available


  275. CHEN Z, Wu G, Ye F, Chen G, et al
    High expression of MMP19 is associated with poor prognosis in patients with colorectal cancer.
    BMC Cancer. 2019;19:448.
    PubMed     Abstract available


  276. SUN J, Fei F, Zhang M, Li Y, et al
    The role of (m)SEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer.
    BMC Cancer. 2019;19:450.
    PubMed     Abstract available


  277. PENNEY ME, Parfrey PS, Savas S, Yilmaz YE, et al
    Correction to: A genome-wide association study identifies single nucleotide polymorphisms associated with time-to-metastasis in colorectal cancer.
    BMC Cancer. 2019;19:437.
    PubMed     Abstract available


  278. NAKAGAWA-SENDA H, Hori M, Matsuda T, Ito H, et al
    Prognostic impact of tumor location in colon cancer: the Monitoring of Cancer Incidence in Japan (MCIJ) project.
    BMC Cancer. 2019;19:431.
    PubMed     Abstract available


  279. PRIETO SP, Reed CL, James HM, Quinn KP, et al
    Differences in colonic crypt morphology of spontaneous and colitis-associated murine models via second harmonic generation imaging to quantify colon cancer development.
    BMC Cancer. 2019;19:428.
    PubMed     Abstract available


  280. HENDRICKS A, Gieseler F, Nazzal S, Brasen JH, et al
    Prognostic relevance of topoisomerase II alpha and minichromosome maintenance protein 6 expression in colorectal cancer.
    BMC Cancer. 2019;19:429.
    PubMed     Abstract available


  281. LEE DW, Han SW, Cha Y, Bae JM, et al
    Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
    BMC Cancer. 2019;19:421.
    PubMed     Abstract available


  282. HINES RB, Jiban MJH, Specogna AV, Vishnubhotla P, et al
    The association between post-treatment surveillance testing and survival in stage II and III colon cancer patients: An observational comparative effectiveness study.
    BMC Cancer. 2019;19:418.
    PubMed     Abstract available


    April 2019
  283. LEE JL, Lim SB, Yu CS, Park IJ, et al
    Local excision in mid-to-low rectal cancer patients who revealed clinically total or near-total regression after preoperative chemoradiotherapy; a proposed trial.
    BMC Cancer. 2019;19:404.
    PubMed     Abstract available


  284. BUNDGAARD-NIELSEN C, Baandrup UT, Nielsen LP, Sorensen S, et al
    The presence of bacteria varies between colorectal adenocarcinomas, precursor lesions and non-malignant tissue.
    BMC Cancer. 2019;19:399.
    PubMed     Abstract available


  285. ROVERS KP, Bakkers C, Simkens GAAM, Burger JWA, et al
    Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, ra
    BMC Cancer. 2019;19:390.
    PubMed     Abstract available


  286. DULSKAS A, Cereska V, Zurauskas E, Stratilatovas E, et al
    Prostate cancer solitary metastasis to anal canal: case report and review of literature.
    BMC Cancer. 2019;19:374.
    PubMed     Abstract available


  287. DE MESQUITA GHA, Carvalho BJ, de Almeida Medeiros KA, Nii F, et al
    Intussusception reveals MUTYH-associated polyposis syndrome and colorectal cancer: a case report.
    BMC Cancer. 2019;19:324.
    PubMed     Abstract available


  288. BUISMAN FE, Homs MYV, Grunhagen DJ, Filipe WF, et al
    Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.
    BMC Cancer. 2019;19:327.
    PubMed     Abstract available


  289. WU YY, Zhang X, Qin YY, Qin JQ, et al
    Mean platelet volume/platelet count ratio in colorectal cancer: a retrospective clinical study.
    BMC Cancer. 2019;19:314.
    PubMed     Abstract available


  290. ROTHE F, Maetens M, Rouas G, Paesmans M, et al
    CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.
    BMC Cancer. 2019;19:304.
    PubMed     Abstract available


  291. GARCIA-TORRECILLAS JM, Olvera-Porcel MC, Ferrer-Marquez M, Rubio-Gil F, et al
    Spatial and temporal variations in Spain in the standardised ratio of in-hospital mortality due to colorectal cancer, 2008-2014.
    BMC Cancer. 2019;19:310.
    PubMed     Abstract available


  292. KIM E, Jung S, Park WS, Lee JH, et al
    Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma: analysis of TCGA data.
    BMC Cancer. 2019;19:302.
    PubMed     Abstract available


    March 2019
  293. SANDBERG TP, Stuart MPME, Oosting J, Tollenaar RAEM, et al
    Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer.
    BMC Cancer. 2019;19:284.
    PubMed     Abstract available


  294. ZHENG B, Wang X, Wei M, Wang Q, et al
    First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:280.
    PubMed     Abstract available


  295. HARLE A, Guillet J, Thomas J, Demange J, et al
    HPV insertional pattern as a personalized tumor marker for the optimized tumor diagnosis and follow-up of patients with HPV-associated carcinomas: a case report.
    BMC Cancer. 2019;19:277.
    PubMed     Abstract available


  296. BOWLES EJA, Yu O, Ziebell R, Chen L, et al
    Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study.
    BMC Cancer. 2019;19:270.
    PubMed     Abstract available


  297. HARADA K, Okamoto W, Mimaki S, Kawamoto Y, et al
    Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
    BMC Cancer. 2019;19:255.
    PubMed     Abstract available


  298. BASTIAENEN VP, Klaver CEL, Kok NFM, de Wilt JHW, et al
    Second and third look laparoscopy in pT4 colon cancer patients for early detection of peritoneal metastases; the COLOPEC 2 randomized multicentre trial.
    BMC Cancer. 2019;19:254.
    PubMed     Abstract available


  299. SHIBUTANI M, Maeda K, Nagahara H, Fukuoka T, et al
    The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study.
    BMC Cancer. 2019;19:241.
    PubMed     Abstract available


  300. VAN BLARIGAN EL, Chan H, Van Loon K, Kenfield SA, et al
    Self-monitoring and reminder text messages to increase physical activity in colorectal cancer survivors (Smart Pace): a pilot randomized controlled trial.
    BMC Cancer. 2019;19:218.
    PubMed     Abstract available


  301. KAZLAUSKAS A, Darinskas A, Meskys R, Tamasauskas A, et al
    Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
    BMC Cancer. 2019;19:197.
    PubMed     Abstract available


  302. HUMMEL S, Kohlmann W, Kollmeyer TM, Jenkins R, et al
    The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database.
    BMC Cancer. 2019;19:190.
    PubMed     Abstract available


    February 2019
  303. JI H, Lu L, Huang J, Liu Y, et al
    IL1A polymorphisms is a risk factor for colorectal cancer in Chinese Han population: a case control study.
    BMC Cancer. 2019;19:181.
    PubMed     Abstract available


  304. TANABE T, Shida D, Tsukamoto S, Morizono G, et al
    Metachronous metastasis to inguinal lymph nodes from sigmoid colon adenocarcinoma with abdominal wall metastasis: a case report.
    BMC Cancer. 2019;19:180.
    PubMed     Abstract available


  305. KLEMENT RJ, Abbasi-Senger N, Adebahr S, Alheid H, et al
    The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases.
    BMC Cancer. 2019;19:173.
    PubMed     Abstract available


  306. WANG Y, Jiang T, Jiang M, Gu S, et al
    Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis.
    BMC Cancer. 2019;19:177.
    PubMed     Abstract available


  307. MJELLE R, Sjursen W, Thommesen L, Saetrom P, et al
    Small RNA expression from viruses, bacteria and human miRNAs in colon cancer tissue and its association with microsatellite instability and tumor location.
    BMC Cancer. 2019;19:161.
    PubMed     Abstract available


  308. CHEN M, Sharma A, Lin Y, Wu Y, et al
    Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells.
    BMC Cancer. 2019;19:153.
    PubMed     Abstract available


  309. KHAN OF, Cusano E, Raissouni S, Pabia M, et al
    Immediate-term cognitive impairment following intravenous (IV) chemotherapy: a prospective pre-post design study.
    BMC Cancer. 2019;19:150.
    PubMed     Abstract available


  310. ERIKSEN AC, Sorensen FB, Lindebjerg J, Hager H, et al
    Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort.
    BMC Cancer. 2019;19:142.
    PubMed     Abstract available


  311. CHARETTE N, Vandeputte C, Ameye L, Bogaert CV, et al
    Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.
    BMC Cancer. 2019;19:134.
    PubMed     Abstract available


  312. PENNEY ME, Parfrey PS, Savas S, Yilmaz YE, et al
    A genome-wide association study identifies single nucleotide polymorphisms associated with time-to-metastasis in colorectal cancer.
    BMC Cancer. 2019;19:133.
    PubMed     Abstract available


  313. LUO ZW, Zhu MG, Zhang ZQ, Ye FJ, et al
    Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis.
    BMC Cancer. 2019;19:123.
    PubMed     Abstract available


  314. SCHUURHUIZEN CSEW, Braamse AMJ, Konings IRHM, Verheul HMW, et al
    Predictors for use of psychosocial services in patients with metastatic colorectal cancer receiving first line systemic treatment.
    BMC Cancer. 2019;19:115.
    PubMed     Abstract available


    January 2019
  315. VAN ROOIJEN S, Carli F, Dalton S, Thomas G, et al
    Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation.
    BMC Cancer. 2019;19:98.
    PubMed     Abstract available


  316. CASTELLANO-CASTILLO D, Morcillo S, Crujeiras AB, Sanchez-Alcoholado L, et al
    Association between serum 25-hydroxyvitamin D and global DNA methylation in visceral adipose tissue from colorectal cancer patients.
    BMC Cancer. 2019;19:93.
    PubMed     Abstract available


  317. LI B, Wang Y, Yin L, Huang G, et al
    Glucocorticoids promote the development of azoxymethane and dextran sulfate sodium-induced colorectal carcinoma in mice.
    BMC Cancer. 2019;19:94.
    PubMed     Abstract available


  318. CAI SR, Huang YQ, Zhang SZ, Li QL, et al
    Effects of subitems in the colorectal cancer screening protocol on the Chinese colorectal cancer screening program: an analysis based on natural community screening results.
    BMC Cancer. 2019;19:47.
    PubMed     Abstract available


  319. XIN H, Wang C, Liu Z
    miR-196a-5p promotes metastasis of colorectal cancer via targeting IkappaBalpha.
    BMC Cancer. 2019;19:30.
    PubMed     Abstract available


  320. CHANG J, Lin G, Ye M, Tong D, et al
    Decreased mean platelet volume predicts poor prognosis in metastatic colorectal cancer patients treated with first-line chemotherapy: results from mCRC biomarker study.
    BMC Cancer. 2019;19:15.
    PubMed     Abstract available


    December 2018
  321. TIAN P, Zhu Y, Zhang C, Guo X, et al
    Ras-ERK1/2 signaling contributes to the development of colorectal cancer via regulating H3K9ac.
    BMC Cancer. 2018;18:1286.
    PubMed     Abstract available


  322. XU Y, Yang X, Gao D, Yang L, et al
    Dihomo-gamma-linolenic acid inhibits xenograft tumor growth in mice bearing shRNA-transfected HCA-7 cells targeting delta-5-desaturase.
    BMC Cancer. 2018;18:1268.
    PubMed     Abstract available


  323. BARRESI V, Cinnirella G, Valenti G, Spampinato G, et al
    Gene expression profiles in genome instability-based classes of colorectal cancer.
    BMC Cancer. 2018;18:1265.
    PubMed     Abstract available


  324. LIN Z, Liu J, Peng L, Zhang D, et al
    Complete pathological response following neoadjuvant FOLFOX chemotherapy in BRCA2-mutant locally advanced rectal cancer: a case report.
    BMC Cancer. 2018;18:1253.
    PubMed     Abstract available


  325. LIU M, Sun W, Cai YY, Wu HZ, et al
    Validation of Quality of Life Instruments for Cancer Patients - Colorectal Cancer (QLICP-CR) in patients with colorectal cancer in Northeast China.
    BMC Cancer. 2018;18:1228.
    PubMed     Abstract available


  326. ALSHERIDAH N, Akhtar S
    Diet, obesity and colorectal carcinoma risk: results from a national cancer registry-based middle-eastern study.
    BMC Cancer. 2018;18:1227.
    PubMed     Abstract available


  327. DEN BAKKER CM, Schaafsma FG, Huirne JAF, Consten ECJ, et al
    Cancer survivors' needs during various treatment phases after multimodal treatment for colon cancer - is there a role for eHealth?
    BMC Cancer. 2018;18:1207.
    PubMed     Abstract available


  328. OYEYEMI SO, Braaten T, Licaj I, Lund E, et al
    Physical activity patterns and the risk of colorectal cancer in the Norwegian Women and Cancer study: a population-based prospective study.
    BMC Cancer. 2018;18:1216.
    PubMed     Abstract available


  329. PETRERA M, Paleari L, Clavarezza M, Puntoni M, et al
    The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 x 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.
    BMC Cancer. 2018;18:1210.
    PubMed     Abstract available


  330. FORTEA-SANCHIS C, Martinez-Ramos D, Escrig-Sos J
    The lymph node status as a prognostic factor in colon cancer: comparative population study of classifications using the logarithm of the ratio between metastatic and nonmetastatic nodes (LODDS) versus the pN-TNM classification and ganglion ratio syste
    BMC Cancer. 2018;18:1208.
    PubMed     Abstract available


  331. JANG M, Kwon Y, Kim H, Kim H, et al
    Microsatellite instability test using peptide nucleic acid probe-mediated melting point analysis: a comparison study.
    BMC Cancer. 2018;18:1218.
    PubMed     Abstract available


  332. DIMITRIOU N, Felekouras E, Karavokyros I, Alexandrou A, et al
    Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients.
    BMC Cancer. 2018;18:1202.
    PubMed     Abstract available


    November 2018
  333. POMPSCH M, Vogel J, Classen F, Kranz P, et al
    The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia.
    BMC Cancer. 2018;18:1190.
    PubMed     Abstract available


  334. RATJEN I, Schafmayer C, Enderle J, di Giuseppe R, et al
    Health-related quality of life in long-term survivors of colorectal cancer and its association with all-cause mortality: a German cohort study.
    BMC Cancer. 2018;18:1156.
    PubMed     Abstract available


  335. CHEN Y, Tan F, Wei L, Li X, et al
    Sleep duration and the risk of cancer: a systematic review and meta-analysis including dose-response relationship.
    BMC Cancer. 2018;18:1149.
    PubMed     Abstract available


  336. YAMAURA M, Yamada T, Watanabe R, Kawai H, et al
    Anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease, successfully treated with modified FOLFOX6: a case report.
    BMC Cancer. 2018;18:1142.
    PubMed     Abstract available


  337. HU H, Huang J, Lan P, Wang L, et al
    CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: a post-hoc analysis of FOWARC trial.
    BMC Cancer. 2018;18:1145.
    PubMed     Abstract available


  338. KASPER S, Kisro J, Fuchs M, Muller C, et al
    Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
    BMC Cancer. 2018;18:1124.
    PubMed     Abstract available


  339. SHARAF LK, Sharma M, Chandel D, Shukla G, et al
    Prophylactic intervention of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis.
    BMC Cancer. 2018;18:1111.
    PubMed     Abstract available


  340. WANG F, He W, Jiang C, Guo G, et al
    Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer.
    BMC Cancer. 2018;18:1102.
    PubMed     Abstract available


  341. LIU FR, Bai S, Feng Q, Pan XY, et al
    Anti-colorectal cancer effects of anti-p21Ras scFv delivered by the recombinant adenovirus KGHV500 and cytokine-induced killer cells.
    BMC Cancer. 2018;18:1087.
    PubMed     Abstract available


  342. BELLUCO C, Forlin M, Delrio P, Rega D, et al
    Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.
    BMC Cancer. 2018;18:1094.
    PubMed     Abstract available


  343. TIAN Y, Li J, Zhou T, Tong D, et al
    Spatially varying effects of predictors for the survival prediction of nonmetastatic colorectal Cancer.
    BMC Cancer. 2018;18:1084.
    PubMed     Abstract available


  344. YU P, Zhou M, Qu J, Fu L, et al
    The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients.
    BMC Cancer. 2018;18:1076.
    PubMed     Abstract available


  345. ASHKTORAB H, Rahi H, Nouraie M, Shokrani B, et al
    GPNMB methylation: a new marker of potentially carcinogenic colon lesions.
    BMC Cancer. 2018;18:1068.
    PubMed     Abstract available


  346. NAGATA N, Nishijima T, Niikura R, Yokoyama T, et al
    Increased risk of non-AIDS-defining cancers in Asian HIV-infected patients: a long-term cohort study.
    BMC Cancer. 2018;18:1066.
    PubMed     Abstract available


  347. MAHMOOD S, English DR, MacInnis RJ, Karahalios A, et al
    Domain-specific physical activity and the risk of colorectal cancer: results from the Melbourne Collaborative Cohort Study.
    BMC Cancer. 2018;18:1063.
    PubMed     Abstract available


  348. LEE CH, Im EJ, Moon PG, Baek MC, et al
    Discovery of a diagnostic biomarker for colon cancer through proteomic profiling of small extracellular vesicles.
    BMC Cancer. 2018;18:1058.
    PubMed     Abstract available


  349. CRUZ-NOVA P, Schnoor M, Correa-Basurto J, Bello M, et al
    The small organic molecule C19 binds and strengthens the KRAS4b-PDEdelta complex and inhibits growth of colorectal cancer cells in vitro and in vivo.
    BMC Cancer. 2018;18:1056.
    PubMed     Abstract available


    October 2018
  350. KAERLEV L, Iachina M, Trosko O, Qvist N, et al
    Colon cancer patients with a serious psychiatric disorder present with a more advanced cancer stage and receive less adjuvant chemotherapy - A Nationwide Danish Cohort Study.
    BMC Cancer. 2018;18:1050.
    PubMed     Abstract available


  351. YE X, Mo M, Xu S, Yang Q, et al
    The hypermethylation of p16 gene exon 1 and exon 2: potential biomarkers for colorectal cancer and are associated with cancer pathological staging.
    BMC Cancer. 2018;18:1023.
    PubMed     Abstract available


  352. O'GORMAN C, Stack J, O'Ceilleachair A, Denieffe S, et al
    Colorectal cancer survivors: an investigation of symptom burden and influencing factors.
    BMC Cancer. 2018;18:1022.
    PubMed     Abstract available


  353. ZENG Z, Yang H, Xiao S
    ACTL6A expression promotes invasion, metastasis and epithelial mesenchymal transition of colon cancer.
    BMC Cancer. 2018;18:1020.
    PubMed     Abstract available


  354. PERTTULA K, Schiffman C, Edmands WMB, Petrick L, et al
    Untargeted lipidomic features associated with colorectal cancer in a prospective cohort.
    BMC Cancer. 2018;18:996.
    PubMed     Abstract available


  355. SPERLICH A, Balmert A, Doll D, Bauer S, et al
    Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer.
    BMC Cancer. 2018;18:998.
    PubMed     Abstract available


  356. SHIGEMATSU Y, Inamura K, Yamamoto N, Mise Y, et al
    Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis.
    BMC Cancer. 2018;18:980.
    PubMed     Abstract available


  357. WANG X, Zamdborg L, Ye H, Grills IS, et al
    A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer.
    BMC Cancer. 2018;18:962.
    PubMed     Abstract available


  358. SHI J, Fei J, Yi Q, Shen L, et al
    Treatment of colon cancer in a patient with systemic lupus erythematosus: a case report.
    BMC Cancer. 2018;18:961.
    PubMed     Abstract available


  359. DOTE S, Itakura S, Kamei K, Hira D, et al
    Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study.
    BMC Cancer. 2018;18:957.
    PubMed     Abstract available


  360. MIZOTA Y, Kanemitsu Y, Tsukamoto S, Shida D, et al
    ROK study-C (Rainbow of KIBOU study-colorectum): a colorectal cancer survivor cohort study on food, nutrition, physical activity, psychosocial factors and its influences on colorectal cancer recurrence, survival and quality of life in Japan.
    BMC Cancer. 2018;18:953.
    PubMed     Abstract available


  361. CANTERO-CID R, Casas-Martin J, Hernandez-Jimenez E, Cubillos-Zapata C, et al
    PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
    BMC Cancer. 2018;18:945.
    PubMed     Abstract available


    September 2018
  362. YANG L, Xiong Z, Xie QK, He W, et al
    Second primary colorectal cancer after the initial primary colorectal cancer.
    BMC Cancer. 2018;18:931.
    PubMed     Abstract available


  363. DOS SANTOS JS, Bonafe GA, Pereira JA, Kanno DT, et al
    Rare perianal extramammary Paget disease successfully treated using topical Imiquimod therapy.
    BMC Cancer. 2018;18:921.
    PubMed     Abstract available


  364. TIKK K, Czock D, Haefeli WE, Kopp-Schneider A, et al
    Clinical trial protocol of the ASTER trial: a double-blind, randomized, placebo-controlled phase III trial evaluating the use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasms.
    BMC Cancer. 2018;18:914.
    PubMed     Abstract available


  365. WHITE A, Ironmonger L, Steele RJC, Ormiston-Smith N, et al
    A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK.
    BMC Cancer. 2018;18:906.
    PubMed     Abstract available


  366. LI N, Zhou W, Zhao L, Zhou J, et al
    Endometriosis-associated recto-sigmoid cancer: a case report.
    BMC Cancer. 2018;18:905.
    PubMed     Abstract available


  367. SEIDENSTICKER R, Damm R, Enge J, Seidensticker M, et al
    Local ablation or radioembolization of colorectal cancer metastases: comorbidities or older age do not affect overall survival.
    BMC Cancer. 2018;18:882.
    PubMed     Abstract available


  368. SCHLIEMANN D, Donnelly M, Dahlui M, Loh SY, et al
    The 'Be Cancer Alert Campaign': protocol to evaluate a mass media campaign to raise awareness about breast and colorectal cancer in Malaysia.
    BMC Cancer. 2018;18:881.
    PubMed     Abstract available


  369. MENDEZ LC, Hsieh E, Earle CC, Wong S, et al
    Synchronous anal canal carcinoma in a heterosexual couple.
    BMC Cancer. 2018;18:884.
    PubMed     Abstract available


  370. HO V, Chung L, Singh A, Lea V, et al
    Overexpression of the MRE11-RAD50-NBS1 (MRN) complex in rectal cancer correlates with poor response to neoadjuvant radiotherapy and prognosis.
    BMC Cancer. 2018;18:869.
    PubMed     Abstract available


    August 2018
  371. DURINIKOVA E, Kozovska Z, Poturnajova M, Plava J, et al
    ALDH1A3 upregulation and spontaneous metastasis formation is associated with acquired chemoresistance in colorectal cancer cells.
    BMC Cancer. 2018;18:848.
    PubMed     Abstract available


  372. LUALDI M, Cavalleri A, Battaglia L, Colombo A, et al
    Early detection of colorectal adenocarcinoma: a clinical decision support tool based on plasma porphyrin accumulation and risk factors.
    BMC Cancer. 2018;18:841.
    PubMed     Abstract available


  373. SUN X, Ju T, Cummings RD
    Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers.
    BMC Cancer. 2018;18:827.
    PubMed     Abstract available


  374. SABER MM, Al-Mahallawi AM, Nassar NN, Stork B, et al
    Targeting colorectal cancer cell metabolism through development of cisplatin and metformin nano-cubosomes.
    BMC Cancer. 2018;18:822.
    PubMed     Abstract available


  375. PUIJK RS, Ruarus AH, Vroomen LGPH, van Tilborg AAJM, et al
    Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial.
    BMC Cancer. 2018;18:821.
    PubMed     Abstract available


  376. RUDERMAN S, Eshein A, Valuckaite V, Dougherty U, et al
    Early increase in blood supply (EIBS) is associated with tumor risk in the Azoxymethane model of colon cancer.
    BMC Cancer. 2018;18:814.
    PubMed     Abstract available


  377. TOSI D, Perez-Gracia E, Atis S, Vie N, et al
    Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
    BMC Cancer. 2018;18:812.
    PubMed     Abstract available


  378. LAN L, Liu H, Smith AR, Appelman C, et al
    Natural product derivative Gossypolone inhibits Musashi family of RNA-binding proteins.
    BMC Cancer. 2018;18:809.
    PubMed     Abstract available


  379. REDMOND HP, Neary PM, Jinih M, O'Connell E, et al
    RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer - the S.U.R.G.U.V.A.N.T. trial.
    BMC Cancer. 2018;18:794.
    PubMed     Abstract available


  380. LI N, Chen M, Cao Y, Li H, et al
    Bcl-2-associated athanogene 3(BAG3) is associated with tumor cell proliferation, migration, invasion and chemoresistance in colorectal cancer.
    BMC Cancer. 2018;18:793.
    PubMed     Abstract available


  381. GOERE D, Pignon JP, Gelli M, Elias D, et al
    Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
    BMC Cancer. 2018;18:787.
    PubMed     Abstract available


  382. KORDOWSKI F, Kolarova J, Schafmayer C, Buch S, et al
    Aberrant DNA methylation of ADAMTS16 in colorectal and other epithelial cancers.
    BMC Cancer. 2018;18:796.
    PubMed     Abstract available


    July 2018
  383. CHIU KWH, Lam KO, An H, Cheung GTC, et al
    Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis.
    BMC Cancer. 2018;18:776.
    PubMed     Abstract available


  384. MOGENSEN MB, Rossing M, Ostrup O, Larsen PN, et al
    Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing.
    BMC Cancer. 2018;18:752.
    PubMed     Abstract available


  385. LEERMAKERS L, Doking S, Thewes B, Braamse AMJ, et al
    Study protocol of the CORRECT multicenter trial: the efficacy of blended cognitive behavioral therapy for reducing psychological distress in colorectal cancer survivors.
    BMC Cancer. 2018;18:748.
    PubMed     Abstract available


  386. TIKK K, Weigl K, Hoffmeister M, Igel S, et al
    Study protocol of the RaPS study: novel risk adapted prevention strategies for people with a family history of colorectal cancer.
    BMC Cancer. 2018;18:720.
    PubMed     Abstract available


    June 2018
  387. MOLNAR B, Galamb O, Peterfia B, Wichmann B, et al
    Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations.
    BMC Cancer. 2018;18:695.
    PubMed     Abstract available


  388. YOUNG EL, Thompson BA, Neklason DW, Firpo MA, et al
    Pancreatic cancer as a sentinel for hereditary cancer predisposition.
    BMC Cancer. 2018;18:697.
    PubMed     Abstract available


  389. CRESPO A, Garcia-Suarez O, Fernandez-Vega I, Solis-Hernandez MP, et al
    Heparan sulfate proteoglycans undergo differential expression alterations in left sided colorectal cancer, depending on their metastatic character.
    BMC Cancer. 2018;18:687.
    PubMed     Abstract available


  390. BOCKELMAN C, Beilmann-Lehtonen I, Kaprio T, Koskensalo S, et al
    Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer.
    BMC Cancer. 2018;18:679.
    PubMed     Abstract available


  391. NEILSEN BK, Chakraborty B, McCall JL, Frodyma DE, et al
    WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage.
    BMC Cancer. 2018;18:673.
    PubMed     Abstract available


  392. KOZOVSKA Z, Patsalias A, Bajzik V, Durinikova E, et al
    ALDH1A inhibition sensitizes colon cancer cells to chemotherapy.
    BMC Cancer. 2018;18:656.
    PubMed     Abstract available


  393. PANATO C, Abusamaan K, Bidoli E, Hamdi-Cherif M, et al
    Survival after the diagnosis of breast or colorectal cancer in the GAZA Strip from 2005 to 2014.
    BMC Cancer. 2018;18:632.
    PubMed     Abstract available


  394. GUAN X, Wang Y, Hu H, Zhao Z, et al
    Reconsideration of the optimal minimum lymph node count for young colon cancer patients: a population-based study.
    BMC Cancer. 2018;18:623.
    PubMed     Abstract available


    May 2018
  395. VANIA L, Rebelo TM, Ferreira E, Weiss SFT, et al
    Knock-down of LRP/LR promotes apoptosis in early and late stage colorectal carcinoma cells via caspase activation.
    BMC Cancer. 2018;18:602.
    PubMed     Abstract available


  396. KIM SC, Shin YK, Kim YA, Jang SG, et al
    Identification of genes inducing resistance to ionizing radiation in human rectal cancer cell lines: re-sensitization of radio-resistant rectal cancer cells through down regulating NDRG1.
    BMC Cancer. 2018;18:594.
    PubMed     Abstract available


  397. GONG X, Chen Z, Han Q, Chen C, et al
    Sanguinarine triggers intrinsic apoptosis to suppress colorectal cancer growth through disassociation between STRAP and MELK.
    BMC Cancer. 2018;18:578.
    PubMed     Abstract available


  398. PRICOLO VE, Bonvini M, Abelli CF
    Patterns of care for anal cancer in the United States - a comparison between academic and community cancer centers.
    BMC Cancer. 2018;18:567.
    PubMed     Abstract available


  399. YANG L, Xiong Z, Xie Q, He W, et al
    Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer.
    BMC Cancer. 2018;18:558.
    PubMed     Abstract available


  400. DE-MASI A, Davis E, Cuming T, Chindawi N, et al
    The acceptability of high resolution anoscopy examination in patients attending a tertiary referral centre.
    BMC Cancer. 2018;18:554.
    PubMed     Abstract available


  401. SHULDINER J, Liu Y, Lofters A
    Incidence of breast and colorectal cancer among immigrants in Ontario, Canada: a retrospective cohort study from 2004-2014.
    BMC Cancer. 2018;18:537.
    PubMed     Abstract available


  402. KIM CW, Kang BM, Kim IY, Kim JY, et al
    Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    BMC Cancer. 2018;18:538.
    PubMed     Abstract available


  403. RUHL R, Rana S, Kelley K, Espinosa-Diez C, et al
    microRNA-451a regulates colorectal cancer proliferation in response to radiation.
    BMC Cancer. 2018;18:517.
    PubMed     Abstract available


  404. REYNOLDS LM, Bissett IP, Consedine NS
    Emotional predictors of bowel screening: the avoidance-promoting role of fear, embarrassment, and disgust.
    BMC Cancer. 2018;18:518.
    PubMed     Abstract available


  405. DI GIROLAMO C, Walters S, Benitez Majano S, Rachet B, et al
    Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013.
    BMC Cancer. 2018;18:492.
    PubMed     Abstract available


  406. LILES EG, Perrin N, Rosales AG, Smith DH, et al
    Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study.
    BMC Cancer. 2018;18:509.
    PubMed     Abstract available


    April 2018
  407. MEI Z, Shao YW, Lin P, Cai X, et al
    SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.
    BMC Cancer. 2018;18:479.
    PubMed     Abstract available


  408. FORSTER I, Brockmann M, Schildgen O, Schildgen V, et al
    Microsatellite instability testing in colorectal cancer using the QiaXcel advanced platform.
    BMC Cancer. 2018;18:484.
    PubMed     Abstract available


  409. HEALY MA, Morris AM, Abrahamse P, Ward KC, et al
    The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program.
    BMC Cancer. 2018;18:481.
    PubMed     Abstract available


  410. ZICHI C, Tampellini M, Tucci M, Sonetto C, et al
    FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report.
    BMC Cancer. 2018;18:470.
    PubMed     Abstract available


  411. BRONZWAER MES, Greuter MJE, Bleijenberg AGC, IJspeert JEG, et al
    Impact of differences in adenoma and proximal serrated polyp detection rate on the long-term effectiveness of FIT-based colorectal cancer screening.
    BMC Cancer. 2018;18:465.
    PubMed     Abstract available


  412. ARROSPIDE A, Idigoras I, Mar J, de Koning H, et al
    Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model.
    BMC Cancer. 2018;18:464.
    PubMed     Abstract available


  413. MUNKER S, Gerken M, Fest P, Ott C, et al
    Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects.
    BMC Cancer. 2018;18:455.
    PubMed     Abstract available


  414. MENG H, Li W, Boardman LA, Wang L, et al
    Loss of ZG16 is associated with molecular and clinicopathological phenotypes of colorectal cancer.
    BMC Cancer. 2018;18:433.
    PubMed     Abstract available


  415. FANG HJ, Shan SB, Zhou YH, Zhong LY, et al
    Diabetes mellitus and the risk of gastrointestinal cancer in women compared with men: a meta-analysis of cohort studies.
    BMC Cancer. 2018;18:422.
    PubMed     Abstract available


  416. GAUTHE M, Richard-Molard M, Rigault E, Buecher B, et al
    Prognostic value of serum CYFRA 21-1 1 in patients with anal canal squamous cell carcinoma treated with radio(chemo)therapy.
    BMC Cancer. 2018;18:417.
    PubMed     Abstract available


  417. SHINOZAKI E, Tanabe K, Akiyoshi T, Tsuchida T, et al
    Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker.
    BMC Cancer. 2018;18:406.
    PubMed     Abstract available


  418. SORIANO LC, Soriano-Gabarro M, Garcia Rodriguez LA
    Trends in the contemporary incidence of colorectal cancer and patient characteristics in the United Kingdom: a population-based cohort study using The Health Improvement Network.
    BMC Cancer. 2018;18:402.
    PubMed     Abstract available


  419. DA COSTA PLN, Wynne D, Fifis T, Nguyen L, et al
    The kallikrein-Kinin system modulates the progression of colorectal liver metastases in a mouse model.
    BMC Cancer. 2018;18:382.
    PubMed     Abstract available


  420. WANG H, Chen X, Liu H, Mou T, et al
    Laparoscopy-assisted colectomy as an Oncologically safe alternative for patients with stage T4 Colon Cancer: a propensity-matched cohort study.
    BMC Cancer. 2018;18:370.
    PubMed     Abstract available


  421. SHIBUTANI M, Maeda K, Nagahara H, Fukuoka T, et al
    A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study.
    BMC Cancer. 2018;18:371.
    PubMed     Abstract available


  422. SANDRA-PETRESCU F, Herrle F, Burkholder I, Kienle P, et al
    Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial.
    BMC Cancer. 2018;18:369.
    PubMed     Abstract available


  423. SHIN HY, Suh M, Choi KS, Hwang SH, et al
    Higher satisfaction with an alternative collection device for stool sampling in colorectal cancer screening with fecal immunochemical test: a cross-sectional study.
    BMC Cancer. 2018;18:365.
    PubMed     Abstract available


  424. SHEN MH, Chen LP, Ho TF, Shih YY, et al
    Validation of the Taiwan Chinese version of the EORTC QLQ-CR29 to assess quality of life in colorectal cancer patients.
    BMC Cancer. 2018;18:353.
    PubMed     Abstract available


    March 2018
  425. SHIDA D, Ahiko Y, Tanabe T, Yoshida T, et al
    Shorter survival in adolescent and young adult patients, compared to adult patients, with stage IV colorectal cancer in Japan.
    BMC Cancer. 2018;18:334.
    PubMed     Abstract available


  426. HAMASHIMA C, Sano H
    Association between age factors and strategies for promoting participation in gastric and colorectal cancer screenings.
    BMC Cancer. 2018;18:345.
    PubMed     Abstract available


  427. YOUNG JM, Durcinoska I, DeLoyde K, Solomon MJ, et al
    Patterns of follow up and survivorship care for people with colorectal cancer in new South Wales, Australia: a population-based survey.
    BMC Cancer. 2018;18:339.
    PubMed     Abstract available


  428. HUANG EY, Chang JC, Chen HH, Hsu CY, et al
    Carcinoembryonic antigen as a marker of radioresistance in colorectal cancer: a potential role of macrophages.
    BMC Cancer. 2018;18:321.
    PubMed     Abstract available


  429. BUROCK S, Daum S, Keilholz U, Neumann K, et al
    Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial.
    BMC Cancer. 2018;18:297.
    PubMed     Abstract available


  430. TAI LH, Ananth AA, Seth R, Alkayyal A, et al
    Sepsis increases perioperative metastases in a murine model.
    BMC Cancer. 2018;18:277.
    PubMed     Abstract available


  431. GAO P, Huang XZ, Song YX, Sun JX, et al
    Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study.
    BMC Cancer. 2018;18:234.
    PubMed     Abstract available


  432. EL KINANY K, Deoula M, Hatime Z, Bennani B, et al
    Dairy products and colorectal cancer in middle eastern and north African countries: a systematic review.
    BMC Cancer. 2018;18:233.
    PubMed     Abstract available


    February 2018
  433. GRAY RT, Coleman HG, Hughes C, Murray LJ, et al
    Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study.
    BMC Cancer. 2018;18:228.
    PubMed     Abstract available


  434. STRAINIENE E, Binkis M, Urnikyte S, Stankevicius V, et al
    Microenvironment dependent gene expression signatures in reprogrammed human colon normal and cancer cell lines.
    BMC Cancer. 2018;18:222.
    PubMed     Abstract available


  435. KOWALCZYK M, Orlowski M, Siermontowski P, Mucha D, et al
    Occurrence of colorectal aberrant crypt foci depending on age and dietary patterns of patients.
    BMC Cancer. 2018;18:213.
    PubMed     Abstract available


  436. WANG T, Ning K, Sun X, Zhang C, et al
    Glycolysis is essential for chemoresistance induced by transient receptor potential channel C5 in colorectal cancer.
    BMC Cancer. 2018;18:207.
    PubMed     Abstract available


  437. HEUBLEIN S, Albertsmeier M, Pfeifer D, Loehrs L, et al
    Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer.
    BMC Cancer. 2018;18:201.
    PubMed     Abstract available


  438. ARJONA-SANCHEZ A, Barrios P, Boldo-Roda E, Camps B, et al
    HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma.
    BMC Cancer. 2018;18:183.
    PubMed     Abstract available


  439. ZHU Y, Wang PP, Zhai G, Bapat B, et al
    Association of rs2282679 A>C polymorphism in vitamin D binding protein gene with colorectal cancer risk and survival: effect modification by dietary vitamin D intake.
    BMC Cancer. 2018;18:155.
    PubMed     Abstract available


  440. RICHTER J, Kretz AL, Lemke J, Fauler M, et al
    CK1alpha overexpression correlates with poor survival in colorectal cancer.
    BMC Cancer. 2018;18:140.
    PubMed     Abstract available


  441. MARTINEZ-USEROS J, Moreno I, Fernandez-Acenero MJ, Rodriguez-Remirez M, et al
    The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
    BMC Cancer. 2018;18:144.
    PubMed     Abstract available


  442. KLAUCK PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, et al
    Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
    BMC Cancer. 2018;18:136.
    PubMed     Abstract available


  443. OZAKI Y, Shindoh J, Gonoi W, Nishioka Y, et al
    Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
    BMC Cancer. 2018;18:138.
    PubMed     Abstract available


    January 2018
  444. BATTAGLIN F, Schirripa M, Buggin F, Pietrantonio F, et al
    The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.
    BMC Cancer. 2018;18:98.
    PubMed     Abstract available


  445. BUSCH EL, Don PK, Chu H, Richardson DB, et al
    Diagnostic accuracy and prediction increment of markers of epithelial-mesenchymal transition to assess cancer cell detachment from primary tumors.
    BMC Cancer. 2018;18:82.
    PubMed     Abstract available


  446. ENGSTRAND J, Nilsson H, Stromberg C, Jonas E, et al
    Colorectal cancer liver metastases - a population-based study on incidence, management and survival.
    BMC Cancer. 2018;18:78.
    PubMed     Abstract available


  447. WANG X, Chen J, Wang J, Yu F, et al
    Correction to: Metalloproteases meprin-a (MEP1A) is a prognostic biomarker and promotes proliferation and invasion of colorectal cancer.
    BMC Cancer. 2018;18:70.
    PubMed     Abstract available


  448. SHAW E, Farris MS, Stone CR, Derksen JWG, et al
    Effects of physical activity on colorectal cancer risk among family history and body mass index subgroups: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:71.
    PubMed     Abstract available


  449. KONG X, Li J, Cai Y, Tian Y, et al
    A modified TNM staging system for non-metastatic colorectal cancer based on nomogram analysis of SEER database.
    BMC Cancer. 2018;18:50.
    PubMed     Abstract available


  450. DAVIS MM, Freeman M, Shannon J, Coronado GD, et al
    A systematic review of clinic and community intervention to increase fecal testing for colorectal cancer in rural and low-income populations in the United States - How, what and when?
    BMC Cancer. 2018;18:40.
    PubMed     Abstract available


  451. HERNANDEZ RK, Wade SW, Reich A, Pirolli M, et al
    Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.
    BMC Cancer. 2018;18:44.
    PubMed     Abstract available


  452. GU MJ, Huang QC, Bao CZ, Li YJ, et al
    Attributable causes of colorectal cancer in China.
    BMC Cancer. 2018;18:38.
    PubMed     Abstract available


  453. FENNELL LJ, Jamieson S, McKeone D, Corish T, et al
    MLH1-93 G/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAF(V600E) mutation.
    BMC Cancer. 2018;18:35.
    PubMed     Abstract available


  454. DEPCZYNSKI J, Dobbins T, Armstrong B, Lower T, et al
    Comparison of cancer incidence in Australian farm residents 45 years and over, compared to rural non-farm and urban residents - a data linkage study.
    BMC Cancer. 2018;18:33.
    PubMed     Abstract available


  455. FARSHIDFAR F, Kopciuk KA, Hilsden R, McGregor SE, et al
    A quantitative multimodal metabolomic assay for colorectal cancer.
    BMC Cancer. 2018;18:26.
    PubMed     Abstract available


  456. ARAKAWA K, Hata K, Yamamoto Y, Nishikawa T, et al
    Nine primary malignant neoplasms-involving the esophagus, stomach, colon, rectum, prostate, and external ear canal-without microsatellite instability: a case report.
    BMC Cancer. 2018;18:24.
    PubMed     Abstract available


  457. HUEMER F, Thaler J, Piringer G, Hackl H, et al
    Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentose Tumortherapie).
    BMC Cancer. 2018;18:11.
    PubMed     Abstract available


    December 2017
  458. ZHANG K, Wang Y, Yu X, Shi Y, et al
    Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth.
    BMC Cancer. 2017;17:899.
    PubMed     Abstract available


  459. FALKOWSKI S, Woillard JB, Postil D, Tubiana-Mathieu N, et al
    Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study.
    BMC Cancer. 2017;17:901.
    PubMed     Abstract available


  460. SONG N, Shin A, Jung HS, Oh JH, et al
    Effects of interactions between common genetic variants and smoking on colorectal cancer.
    BMC Cancer. 2017;17:869.
    PubMed     Abstract available


  461. SHIN HY, Suh M, Park B, Jun JK, et al
    Perceptions of colorectal cancer screening and recommendation behaviors among physicians in Korea.
    BMC Cancer. 2017;17:860.
    PubMed     Abstract available


  462. YEH YS, Chang YT, Ma CJ, Huang CW, et al
    First-decade patient with colorectal cancer carrying both germline and somatic mutations in APC gene.
    BMC Cancer. 2017;17:849.
    PubMed     Abstract available


  463. CAO B, Luo L, Feng L, Ma S, et al
    A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
    BMC Cancer. 2017;17:844.
    PubMed     Abstract available


  464. BEEBE-DIMMER JL, Yee C, Paskett E, Schwartz AG, et al
    Family history of prostate and colorectal cancer and risk of colorectal cancer in the Women's health initiative.
    BMC Cancer. 2017;17:848.
    PubMed     Abstract available


  465. LEE J, Xiao YY, Sun YY, Balderacchi J, et al
    Prevalence and characteristics of hereditary non-polyposis colorectal cancer (HNPCC) syndrome in immigrant Asian colorectal cancer patients.
    BMC Cancer. 2017;17:843.
    PubMed     Abstract available


  466. VULCAN A, Manjer J, Ohlsson B
    High blood glucose levels are associated with higher risk of colon cancer in men: a cohort study.
    BMC Cancer. 2017;17:842.
    PubMed     Abstract available


  467. COELHO H, Jones-Hughes T, Snowsill T, Briscoe S, et al
    A systematic review of test accuracy studies evaluating molecular micro-satellite instability testing for the detection of individuals with lynch syndrome.
    BMC Cancer. 2017;17:836.
    PubMed     Abstract available


  468. BENEDICTO A, Marquez J, Herrero A, Olaso E, et al
    Decreased expression of the beta2 integrin on tumor cells is associated with a reduction in liver metastasis of colorectal cancer in mice.
    BMC Cancer. 2017;17:827.
    PubMed     Abstract available


  469. ZHOU P, Wang C, Hu Z, Chen W, et al
    Genistein induces apoptosis of colon cancer cells by reversal of epithelial-to-mesenchymal via a Notch1/NF-kappaB/slug/E-cadherin pathway.
    BMC Cancer. 2017;17:813.
    PubMed     Abstract available


    November 2017
  470. HAN VAN KRIEKEN J, Kafatos G, Bennett J, Mineur L, et al
    Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.
    BMC Cancer. 2017;17:798.
    PubMed     Abstract available


  471. YANG J, Du XL, Li S, Wu Y, et al
    The risk and survival outcome of subsequent primary colorectal cancer after the first primary colorectal cancer: cases from 1973 to 2012.
    BMC Cancer. 2017;17:783.
    PubMed     Abstract available


  472. THIEBAULT Q, Defossez G, Karayan-Tapon L, Ingrand P, et al
    Analysis of factors influencing molecular testing at diagnostic of colorectal cancer.
    BMC Cancer. 2017;17:765.
    PubMed     Abstract available


  473. STEVANATO FILHO PR, Aguiar Junior S, Begnami MD, Kuasne H, et al
    Oestrogen receptor beta isoform expression in sporadic colorectal cancer, familial adenomatous polyposis and progressive stages of colorectal cancer.
    BMC Cancer. 2017;17:754.
    PubMed     Abstract available


  474. SONG Y, Yang Y, Gao P, Chen X, et al
    The preoperative neutrophil to lymphocyte ratio is a superior indicator of prognosis compared with other inflammatory biomarkers in resectable colorectal cancer.
    BMC Cancer. 2017;17:744.
    PubMed     Abstract available


  475. ALONSO-MOLERO J, Gonzalez-Donquiles C, Fernandez-Villa T, de Souza-Teixeira F, et al
    Alterations in PGC1alpha expression levels are involved in colorectal cancer risk: a qualitative systematic review.
    BMC Cancer. 2017;17:731.
    PubMed     Abstract available


  476. ERNST J, Mehnert A, Dietz A, Hornemann B, et al
    Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients.
    BMC Cancer. 2017;17:741.
    PubMed     Abstract available


  477. TAKAHASHI H, Takahashi M, Ohnuma S, Unno M, et al
    microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer.
    BMC Cancer. 2017;17:723.
    PubMed     Abstract available


  478. YANG C, Zou K, Zheng L, Xiong B, et al
    Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
    BMC Cancer. 2017;17:725.
    PubMed     Abstract available


  479. YU X, Mi L, Dong J, Zou J, et al
    Long intergenic non-protein-coding RNA 1567 (LINC01567) acts as a "sponge" against microRNA-93 in regulating the proliferation and tumorigenesis of human colon cancer stem cells.
    BMC Cancer. 2017;17:716.
    PubMed     Abstract available


    October 2017
  480. STEVENS JR, Herrick JS, Wolff RK, Slattery ML, et al
    Identifying factors associated with the direction and significance of microRNA tumor-normal expression differences in colorectal cancer.
    BMC Cancer. 2017;17:707.
    PubMed     Abstract available


  481. RATJEN I, Schafmayer C, di Giuseppe R, Waniek S, et al
    Postdiagnostic physical activity, sleep duration, and TV watching and all-cause mortality among long-term colorectal cancer survivors: a prospective cohort study.
    BMC Cancer. 2017;17:701.
    PubMed     Abstract available


  482. UNGARI AQ, Pereira LRL, Nunes AA, Peria FM, et al
    Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school.
    BMC Cancer. 2017;17:691.
    PubMed     Abstract available


    August 2017
  483. PARK SM, Lee J, Kim YA, Chang YJ, et al
    Factors related with colorectal and stomach cancer screening practice among disease-free lung cancer survivors in Korea.
    BMC Cancer. 2017;17:600.
    PubMed     Abstract available


    June 2017
  484. COEN M, Rigamonti F, Roth A, Koessler T, et al
    Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature.
    BMC Cancer. 2017;17:394.
    PubMed     Abstract available


    May 2017
  485. DARWANTO A, Hein AM, Strauss S, Kong Y, et al
    Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform.
    BMC Cancer. 2017;17:358.
    PubMed     Abstract available


  486. DE FELICE F, Benevento I, Magnante AL, Musio D, et al
    Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer.
    BMC Cancer. 2017;17:325.
    PubMed     Abstract available


    April 2017
  487. LELONG B, de Chaisemartin C, Meillat H, Cournier S, et al
    A multicentre randomised controlled trial to evaluate the efficacy, morbidity and functional outcome of endoscopic transanal proctectomy versus laparoscopic proctectomy for low-lying rectal cancer (ETAP-GRECCAR 11 TRIAL): rationale and design.
    BMC Cancer. 2017;17:253.
    PubMed     Abstract available


    March 2017
  488. LI X, Lu H, Xu K, Wang H, et al
    Negative lymph node count is an independent prognostic factor for patients with rectal cancer who received preoperative radiotherapy.
    BMC Cancer. 2017;17:227.
    PubMed     Abstract available


  489. BERNTSEN S, Aaronson NK, Buffart L, Borjeson S, et al
    Design of a randomized controlled trial of physical training and cancer (Phys-Can) - the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome.
    BMC Cancer. 2017;17:218.
    PubMed     Abstract available


  490. CERVANTES-MADRID D, Wettergren Y, Falk P, Lundholm K, et al
    DNA alterations in Cd133+ and Cd133- tumour cells enriched from intra-operative human colon tumour biopsies.
    BMC Cancer. 2017;17:219.
    PubMed     Abstract available


  491. FENG YR, Jin J, Ren H, Wang X, et al
    Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate.
    BMC Cancer. 2017;17:182.
    PubMed     Abstract available


  492. FORZATI F, De Martino M, Esposito F, Sepe R, et al
    miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene.
    BMC Cancer. 2017;17:170.
    PubMed     Abstract available


    February 2017
  493. BRUNET J, Burke S, Grocott MP, West MA, et al
    The effects of exercise on pain, fatigue, insomnia, and health perceptions in patients with operable advanced stage rectal cancer prior to surgery: a pilot trial.
    BMC Cancer. 2017;17:153.
    PubMed     Abstract available


  494. SINGH VP, Katta S, Kumar S
    WD-repeat protein WDR13 is a novel transcriptional regulator of c-Jun and modulates intestinal homeostasis in mice.
    BMC Cancer. 2017;17:148.
    PubMed     Abstract available


  495. WEYN C, Van Raemdonck S, Dendooven R, Maes V, et al
    Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples.
    BMC Cancer. 2017;17:139.
    PubMed     Abstract available


  496. PAHLE J, Menzel L, Niesler N, Kobelt D, et al
    Rapid eradication of colon carcinoma by Clostridium perfringens Enterotoxin suicidal gene therapy.
    BMC Cancer. 2017;17:129.
    PubMed     Abstract available


  497. MEDENWALD D, Vordermark D, Dietzel CT
    Cancer mortality in former East and West Germany: a story of unification?
    BMC Cancer. 2017;17:94.
    PubMed     Abstract available


    January 2017
  498. STEVENSON HL, Prats MM, Sasatomi E
    Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
    BMC Cancer. 2017;17:35.
    PubMed     Abstract available


    December 2016
  499. YEDID N, Kalma Y, Malcov M, Amit A, et al
    The effect of a germline mutation in the APC gene on beta-catenin in human embryonic stem cells.
    BMC Cancer. 2016;16:952.
    PubMed     Abstract available


    November 2016
  500. ZHANG J, Ren J, Wei J, Chong CC, et al
    Alternative splicing of estrogen receptor alpha in hepatocellular carcinoma.
    BMC Cancer. 2016;16:926.
    PubMed     Abstract available


  501. STEPPELER C, Sodring M, Paulsen JE
    Colorectal Carcinogenesis in the A/J Min/+ Mouse Model is Inhibited by Hemin, Independently of Dietary Fat Content and Fecal Lipid Peroxidation Rate.
    BMC Cancer. 2016;16:832.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: